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CHAPTER 1 BACKGROUND AND SCOPE OF THE DISSERTATION
1.1 Research motivation
Vaccination holds great promise in the therapeutic treatment of cancer by
leveraging the host’s immune system. Significant advances in cancer immunology have
led to approval of the first therapeutic cancer vaccine by FDA.1 However, the development
of cancer vaccines is still infant. Maximizing therapeutic efficacy while minimizing the side
effects of cancer vaccines remains challenging. One of the major goals for
immunotherapy is to reverse tumor-associated immunosuppression and to restore antitumor immunity in patients. These challenges can be in part addressed through
optimization of cancer vaccines, including formulation, rational design of antigen and
vaccine adjuvants.
Oligonucleotide-based therapeutics, including CpG ODNs (oligodeoxynucleotides),
siRNA, aptamer and antisense have resulted in magnificent efficacy in the treatment of
cancer over the past decades. However, one of the biggest barriers in the clinical
application of these functional oligonucleotide-based therapeutics is the lack of efficient
delivery. For example, CpG ODNs (single-stranded synthetic ODN molecules with
unmethylated deoxycytidyl-deoxyguanosine) are potent immune adjuvants and can
stimulate a wide range of immune cells in vitro. But their applications in vivo have been
compromised mostly due to the lack of efficient delivery as well as their systemic toxicity.
Targeting oligonucleotide-based vaccine adjuvants to lymph nodes and limiting the
systemic dissemination have been shown to greatly improve both the efficacy and safety
profiles.2,3 Recently, the ‘albumin-hitchhiking’ approach demonstrated a viable and
attractive delivery strategy to achieve remarkable therapeutic efficacy and reduce
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systemic toxicity.2 In this approach, a lipophilic lipid tail was covalently conjugated to CpG
ODN and after subcutaneous injection, amphiphilic CpG ODN-adjuvanted vaccines
accumulated in draining lymph nodes (dLNs), which harbored a great number of immune
cells, and induced a 30-fold increase in antigen-specific cytotoxic CD8+ T cells in mice.
Meanwhile, amphiphilic ODN conjugate dramatically reduced CpG-induced toxicity,
overcoming the limitations of CpG ODNs in vivo. Here, we aim to further expand research
scope of the “albumin-hitchhiking” approach in immune modulation by investigating the
therapeutic efficacy of a variety of amphiphilic ODNs, and we also commit to developing
novel adjuvants and drug-delivery strategies that would constitutively improve the
immunogenicity of cancer vaccines and lead to tumor regression.
1.2 Immunological background
To understand how amphiphilic ODNs contribute to immune modulation, it is
important to know how the immune system works. The immune system consists of a
network of lymphoid organs and various immune cells including lymphocytes, dendritic
cells, and natural killer cells. The immune system fulfills a pivotal role in defending the
body against a wide variety of pathogens infections, including bacteria, virus and
parasites, and in preventing the progression of cancer as well.4-6 The responses that the
immune system mounts against foreign pathogens, allergies, self-damaged cells, and
graft are called immune responses, which are generally classified into innate response
and adaptive response.
The innate immune response, which is nonspecific immune response, detects and
recognizes foreign pathogens via PAMPs (pathogen-associated molecular patterns) that
are evolutionarily conserved molecular motifs expressed by a variety of microbes.7,8
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Innate immune cells, like professional antigen presenting cells (APCs) and phagocytes,
detect and recognize PAMPs mainly through Toll-like receptors (TLRs) and other pattern
recognition receptors (PRRs).7 Recognition of PAMPs leads to a cascade of signaling
pathways and activates innate immune cells, triggering phagocytosis of pathogens and
providing the first line of defense against various pathogens. Innate response induces
rapid inflammation due to infection which gives rise to redness, swelling, heat, and pain.
More importantly, innate response is crucial for the initiation of adaptive responses.7,8

Figure 1-1. Schemes of how TLR ligands facilitate innate and adaptive immunity.
The adaptive immune response, on the other hand, is a specific immune response.
The adaptive immune response is primarily dominated by highly specialized lymphocytes
including T cells and B cells. These specialized lymphocytes are activated by APCs that
have completed phagocytosis and process of pathogens or pathogen-associated
antigenic molecules. Once activated, these lymphocytes proliferate and differentiate into
effector cells that specifically eliminate pathogens or suppress their growth and
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proliferation. Other than specificity, another unique characteristic of adaptive immune
response is immunological memory which forms and develops from an original adaptive
immune response to a specific pathogen and can quickly induce a more potent immune
response to the same pathogen in future encounters. Although it appears that adaptive
immune response is more advanced and sophisticated than innate one, innate response
is generally prerequisite to the activation of adaptive response which in return can
enhance innate immunity by effector molecules such as cytokines and antibodies. 7-9 The
role of TLR ligands in bridging innate and adaptive immunity is illustrated in Figure 1-1.
TLR ligands like CpG ODNs directly activate professional APCs, creating an immune
milieu that is abundant in pro-inflammatory and T helper 1 (TH1)-type cytokines. By
enhancing the function of professional APCs, TLR ligands can facilitate the development
of humoral and cellular vaccine-specific immunity.10
1.3 Scope of the dissertation

Figure 1-2. Schemes of entry of lipo ODN into the lymphatics from interstitium.
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In this dissertation, we focus on expanding the scope of the “albumin-hitchhiking”
approach in immune modulation and aim to improve the therapeutic efficacy of cancer
vaccines. The rationale of the “albumin-hijacking” approach is shown in Figure 1-2. Briefly,
small-molecule drugs or moderately sized biomolecules less than 5 nm are preferentially
absorbed from the interstitial space into the blood capillaries rather than lymphatic
capillaries, while increasing molecular size leads to increasing uptake via the
lymphatics.11 We mainly studied immunological roles and physiochemical properties of a
variety of amphiphilic therapeutic molecules, including lipid-conjugated ODNs and PEG
(polyethylene glycol) cargos, in modulating immune activation in vitro and in vivo. We first
evaluated the efficacy of three representative classes of lipid-modified CpG ODNs as
vaccine adjuvants. The results showed that lipid modification on CpG ODN enhanced
cellular uptake in vitro and LN accumulation in vivo. Although lipid conjugation generally
compromised immunostimulatory properties of CpG ODNs in vitro, administration of lipo
CpG class B and C ODNs, not lipo CpG class A ODN, with a protein antigen in mice
resulted in significantly improved antigen-specific CD8+ T cells responses and antibody
responses. We then evaluated the therapeutic efficacy of immunosuppressive ODN A151
and its lipid-modified form in suppressing TLR9-mediated immune responses in vitro and
in vivo. The data demonstrated that lipo ODN A151 exhibited dramatically enhanced
cellular uptake and increased LN accumulation compared to unmodified ODN A151. More
importantly, tolerization with lipo ODN A151, not unmodified ODN A151 in mice, led to
profound suppression of immune responses induced by CpG-adjuvanted vaccines. Next,
we investigated the structure-based retention kinetics of lipid-based amphiphiles
anchored on the plasma membranes of red blood cells (RBCs). We revealed that longer
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lipid tail enabled more stable retention kinetics of amphiphiles anchored on RBCs, while
shorter polyethylene glycerol (PEG) spacer was favored for markedly prolonged
circulation half-life of amphiphiles inserted on RBCs in vivo. Furthermore, cationic
amphiphiles covalently linked with cationic lipid tails demonstrated noticeably improved
retention kinetics on RBCs in vivo compared to the anionic counterparts. Finally, we
discovered a novel class of adjuvant booster that significantly enhanced the adjuvant
potency of TLR7/8 agonists in vitro and in vivo. We found that lipid modification on several
oligonucleotide-based TLR7 inhibitors led to remarkable upregulation of TLR7 agonistinduced NF-κB activation in the presence of serum albumin. Notably, administration of
imiquimod-adjuvanted vaccine laced with the structurally-optimized adjuvant booster in
mice resulted in a five-fold increase in the frequency of antigen-specific CD8+ T cells and
the production of antigen-specific IgG, in comparison with the same molecular vaccine
without the adjuvant booster.
In Chapter 2, we evaluated the immunostimulatory properties of amphiphilic CpG
ODNs. Three representative classes of lipid-conjugated CpG ODNs were synthesized
and their bioactivities as vaccine adjuvants were evaluated. We showed that lipid
modification enhanced the stability of phosphodiester-backboned CpG ODN to nuclease
degradation and the binding between albumin and CpG ODNs. In addition, the data
revealed that lipid modification on CpG ODNs promoted cellular uptake and dramatically
increased LN accumulation. Lipid-modified class A CpG (lipo CpG A) demonstrated
improved stimulatory activities in murine TLR9 reporter cells and bone marrow-derived
dendritic cells (BMDC) in vitro, while lipid modification on class B and C CpG ODNs
decreased the level of TLR9-mediated NF-κB activation and reduced the production of
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pro-inflammatory cytokines in BMDC. However, subcutaneous administration of a protein
antigen ovalbumin (OVA) with lipo CpG B or CpG C, but not lipo CpG A, resulted in
markedly improved OVA-specific IgG response and cytotoxic CD8+ T cell response in
mice compared with unmodified CpG ODN-adjuvanted vaccines. Collectively, we showed
that lipid modification on three representative classes of CpG ODNs differentially
modulated immune responses in vitro and in vivo. This study highlighted the significance
of in vivo LN-targeting delivery of CpG ODNs in improving their efficacy as vaccine
adjuvants.
In chapter 3, we investigated the therapeutic efficacy of lipid-modified
immunosuppressive ODN A151 in inhibiting TLR9-mediated immune activation.
Suppressive ODN A151 encoding TTAGGG motif can downregulate the production of
pro-inflammatory and TH-1-biased cytokines, and therefore can markedly suppress TLR9
agonist-induced immune responses in mice. We modified ODN A151 with an albuminbinding diacyl lipid at its 5’-terminal. We found that lipid-functionalized ODN A151 showed
increased cellular uptake and improved inhibitory capability of suppressing TLR9mediated immune activation in vitro, in comparison with unmodified ODN A151. More
importantly, prophylactic treatment in mice with lipo ODN A151, but not unmodified ODN
A151, led to a five-fold decrease in the frequency of antigen-specific CD8+ T cell and a
significant reduction in the level of OVA-specific IgG in blood. Taken together, these
findings suggested that targeting suppressive ODN to local LNs could be an effective
approach to improving immune modulation. This approach might be utilized for treating
autoimmune disorders with molecular immunomodulators.
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In chapter 4, we analyzed the structure-dependent retention kinetics of lipid-based
amphiphiles anchored on RBCs. We synthesized a variety of polymer amphiphiles with
varying length of lipid tails and PEG spacers. Our results revealed that longer diacyl lipid
chain conjugated amphiphiles exhibited more stable retention on RBCs, while shorter
PEG spacers were favored for markedly prolonged circulation half-life of amphiphiles
anchored on RBCs in vivo. In addition, we identified that blood flow-induced stress and
serum albumin together played pivotal roles in the release of amphiphiles inserted on
RBCs. Furthermore, cationic lipid modification on long PEG spacer strikingly extended
the retention kinetics of amphiphiles anchored on RBCs in vivo and resulted in a 40-fold
increase in circulation half-life in contrast to the anionic analogs. Our results highlighted
the importance of molecular design in the dynamic stability of membrane-anchored
amphiphiles.
In chapter 5, we aimed to evaluate the therapeutic efficacy of lipid-modified
oligonucleotide-based TLR7 inhibitors in treating systemic lupus erythematosus.
However, we discovered that several lipid-modified oligonucleotide-based TLR7 inhibitors
dramatically enhanced TLR7-mediated NF-κB activation rather than suppressed it. We
then revealed that it was due to the presence of albumin that lipid modification
transformed oligonucleotide-based TLR7 inhibitors into TLR7 adjuvant boosters. Besides,
the data showed that these adjuvant boosters were applicable to human cells and could
enhance human TLR7- and TLR8-mediated NF-κB activation. More importantly,
subcutaneous administration of imiquimod-adjuvanted vaccine laced with the adjuvant
booster in mice resulted in a five-fold increase in the expansion of antigen-specific CD8+
T-cells and enhanced antibody response relative to the same molecular vaccine without
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the adjuvant booster. These findings highlighted a novel class of adjuvant booster which
could be used to dramatically improve the immunogenicity of subunit vaccines and might
be broadly applicable to current vaccines.
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CHAPTER 2 IMMUNOSTIMULATORY PROPERTIES OF LIPID-MODIFIED CPG ODN
2.1 Introduction
Bacterial DNA containing the unmethylated CpG dinucleotides motifs (CpG motifs)
in a specific sequence can stimulate mammalian immune cells.12-14 Synthetic
oligonucleotides containing CpG motifs mimic molecular signatures of bacteria and can
activate the vertebrate immune cells via TLR9.12 Discovered and developed in the early
1990s, CpG ODNs have quickly drawn considerable interest due to the great promise of
functioning as molecular adjuvants for vaccines. When co-administered with antigens,
CpG ODNs activate professional APCs and subsequently augment antigen-specific
humoral and cellular immune responses. Current clinical studies have shown that the
utilization of CpG ODNs in human is safe and that CpG ODNs can improve the immune
responses to co-administered antigens.10,13 CpG ODN directly stimulates B cells and
dendritic cells (DCs), giving rise to the induction of both innate and adaptive immunity.
TLR9 recognition is essential in this process. Once TLR9 is engaged by CpG ODNs, B
cells produce IL-6, IL-12 and the CXCR3 chemokines IP-10, and secrete IgM, while DCs
upregulate their expression of costimulatory molecules CD 40, CD86 and MHC
molecules, and increase production of IL-1, IL-6, IL-12, IL-18, and TNF-α.15 Meanwhile,
DCs differentiate to a mature stage where the antigen-presenting function is enhanced,
which in turn, promotes the generation of humoral and cellular vaccine-specific immunity.
Hence, CpG ODN creates an immune milieu where proinflammatory and TH1-type
cytokines are enriched. Moreover, this innate immune response lays a solid foundation
for antigen-specific adaptive immunity.10
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CpG ODNs trigger the secretion of TH1-type and proinflammatory cytokines and
stimulate the maturation of professional APCs. These immunological effects promote the
usage of CpG ODNs as potential vaccine adjuvants or “danger signal” to enhance the
immunogenicity of co-administered antigens. To date, a variety of CpG ODNs have been
utilized to elicit an innate immune response through the TLR9 activation pathway.10,16,17
Afterwards, innate immune responses can lead to the proliferation of cytotoxic CD8 + T
cells and enhance the antigen-specific adaptive immune response against tumor
antigens.10,16,17 Several preclinical studies have been carried out in mice to examine the
immunogenicity of CpG-adjuvanted vaccines, and it is established that CpG ODNs are
adequate to promote the humoral and cellular immune response to proteins such as
ovalbumin.18,19 Several clinical studies have also exploited CpG ODNs in a combination
of cancer vaccines. In melanoma studies, patients immunized with CpG ODN-adjuvanted
vaccines developed >3% of circulating CD8+ T cells that were Melan-A-specific. That was
an order magnitude greater than subjects treated with vaccine alone.20 In addition, in
studies of Energix B, CpG ODN-adjuvanted vaccine induced a more potent and rapid
antibody response. Specifically, subjects treated with CpG ODN-adjuvanted vaccine
resulted in 13-fold greater primary and 45-fold greater secondary serum IgG Ab
responses than those immunized with vaccine only.21,22 Collectively, CpG ODNs function
as excellent adjuvants for cancer vaccines and bioagents for therapeutic treatment.
However, one of the major barriers to extensively utilize CpG ODNs as vaccine
adjuvants in clinical application is lack of efficient delivery to APCs in secondary lymph
organs, such as lymph nodes.2,23,24 In addition, CpG ODNs bridged by phosphodiester
(PO) are vulnerable to rapid degradation by DNase. As a result, DNase-resistant CpG
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ODNs synthesized by chemical modification with phosphorothioate (PS) backbone are
widely studied in vivo.10,16,17 However, significant obstacles stand because of inadequate
accumulation of CpG ODN in the immune system and incompetence of CpG ODN to
penetrate cellular membranes. Regardless of its desirable nucleases resistance, CpG
ODN cannot be readily internalized by APCs after parental immunization due to its small
size, negative charge, and hydrophilic backbone. Recently, we showed that lipid
conjugation at 5’ terminal of class B CpG ODN significantly promoted its cellular uptake
and accumulation in APCs in LNs after subcutaneous injection.2 Lipid conjugated CpG
ODN tightly bound to endogenous albumin and abundantly trafficked to draining LNs
where it was physiologically filtered and accumulated in the APCs. This approach
remarkably improved systemic safety as well as therapeutic efficacy of class B CpG ODN
as vaccine adjuvant.2 Based on their intrinsic sequences, structural characteristics, and
biological activities, CpG ODNs can be classified into three representative types.10,16
These classes of CpG ODNs contain a complete or partial PS backbone and a poly-G tail
at either 3’ or 5’ end, or both ends, and demonstrate structure-based immunostimulatory
properties.10,16 However, whether lipid modification can augment the biological activities
of all three classes of CpG remains unclear. Here we aim to evaluate the immune
stimulatory properties of all three classes of lipid-tagged CpG conjugates (lipo CpG) in
vitro and in vivo, with an emphasis on their adjuvant activities when co-administered with
a protein antigen. Our data confirmed that lipo CpG was able to function as a safe
adjuvant and induced robust antigen-specific immunity evidenced by potent cytotoxic T
cell and humoral responses. In addition, our data clearly suggested the in vitro
immunostimulatory activities of CpG did not suffice to reproduce in vivo vaccine efficacy.
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2.2 Materials and methods
2.2.1 Synthesis of diacyl lipid phosphoramidite
The diacyl lipid phosphoramidite was synthesized as previously described. 2 A
solution of stearoyl chloride (6.789 g, 22.41 mmol) in 1,2-dichloroethane (50 mL) was
added dropwise to a solution of 1,3-diamino-2-dydroxypropane (1.0 g, 11.10 mmol) in the
presence of 1,2-dichloroethane (100 mL) and triethylamine (2.896 g, 22.41 mmol). The
reaction mixture was stirred for 2 h at 25 °C and then heated at 70 °C overnight. The
reaction mixture was then cooled to 25 °C, filtered, and the solid was sequentially washed
with CH2Cl2, CH3OH, 5% NaHCO3 and diethyl ether. The product was dried under vacuum
to give the intermediate product as a white solid (yield: 90%). 1H NMR (300 MHz, CDCl3,
ppm): δ 6.3 (m, 2H), 3.8 (m, 1H), 3.4-3.2 (m, 4H), 2.2 (t, 4H), 1.6 (m, 4H), 1.3-1.2 (m,
60H), 0.9 (t, 6H). The intermediate product (5.8 g, 9.31 mmol) and N, NDiisopropylethylamine (DIPEA, 4.2 mL, 18.62 mmol) was then suspended in anhydrous
CH2Cl2 (100 mL). The mixture was cooled on an ice bath and 2-Cyanoethyl N, Ndiisopropylchlorophosphoramidite (8.6 mL, 0.47 mmol) was added dropwise under dry
nitrogen. After stirring at 25 °C for 1 hour, the solution was heated to 60 °C for 90 min.
The solution was washed with 5% NaHCO3 and brine, dried over Na2SO4 and
concentrated under vacuum. The final product was isolated by precipitation from cold
acetone to afford 4 g (55% yield) lipid phosphoramidite as a white solid. 1H NMR (300
MHz, CDCl3): δ 6.4 (m, 2H), 3.9 (m, 2H), 3.8 (m, 2H), 3.6 (m, 2H), 3.0-2.9 (m, 2H), 2.6 (t,
2H), 2.2 (m, 4H), 1.6 (m, 6H), 1.3-1.2 (m, 72H), 0.9 (t, 6H). 31P NMR (CDCl3): 154 ppm.
2.2.2 Synthesis and purification of oligonucleotides
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All ODN sequences were synthesized using an ABI 394 DNA synthesizer on a 1.0
micromole scale. All lipophilic phosphoramidites were conjugated as a final ‘base’ on the
5’ end of oligos. Lipophilic phosphoramidite was dissolved in dichloromethane and
coupled to oligos in DNA synthesizer (15min coupling time). After the synthesis, DNA was
cleaved from the solid support, deprotected, and purified by reverse phase HPLC using
a C4 column (BioBasic-4, 200mm x 4.6mm, Thermo Scientific), 100mM triethylamineacetic acid buffer (TEAA, pH 7.5)-methanol (0-5min, 50-80%; 5-15min, 80-100%) as an
eluent. Lipophilic ODNs typically eluted at 13min while unconjugated oligos eluted at
7min. Fluorescein label ODNs were synthesized using 3’-(6-Fluorescein) tagged
controlled pore glass. Lipid-conjugated CpG ODN 158525 (Class A CpG: 5'ggGGTCAACGTTGAgggggg-3’),

CpG

ODN

182626

(Class

B

CpG:

5’-

tccatgacgttcctgacgtt-3’), CpG ODN 239527 (Class C CpG: 5'-tcgtcgttttcggcgcgcgccg-3’)
(lower case letters indicate phosphorothioate linkage; capital letters refer to
phosphodiester linkage) were synthesized using the above method.
2.2.3 DNase I protection assay
To evaluate the role of lipid modification in protecting CpG ODNs, three classes of
free CpG ODNs and their lipid-modified counterparts were incubated in the presence of
the DNase I (0.5 unit per μg of ODN) at 37 ℃. At different time points, aliquots of these
samples were collected and were immediately added 2 μL of EDTA (0.5 M) to stop DNase
degradation. Samples were stored at -20 ℃ until subjected to gel electrophoresis
analysis. The integrity of the ODNs in each formulation was compared with untreated
ODNs as a control. The ODN’s stability was further evaluated in freshly isolated mouse
serum. 30 µM free or lipid conjugated CpG A, B, and C (fluorescein labeled at 3’-end)
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were incubated with or without 5 µL mouse plasma serum in PBS (1 X) with a final volume
of 25 µL at 37 ℃ for 8 h. After incubation, 2.5 µL aliquot mixture of each sample was
aspirated to a vial containing 6.5 µL TBE buffer (1X) and 1 µL glycerol. Electrophoresis
was run in 1% agarose gel at 75 V for 10 min, and then the gel was photographed under
UV.
2.2.4 Albumin binding assay
We used a gel electrophoresis mobility shift assay28 to detect albumin protein
complexes with nucleic acids. Solutions of different concentrations of albumin protein and
fluorescein-labeled CpG ODNs in different formulations were combined and incubated in
PBS at 37 ℃ for 2h, the resulting mixtures are subjected to electrophoresis under native
conditions through 1% agarose gel. The dissociation constant (Kd) values were estimated
by using ImageJ software (NIH) to quantitate the fluorescent signal in each ODN band. 28
Background signals from blank regions of the gel were subtracted from the signal
intensities obtained from bands. The fraction of ODN bound was determined from the
background-subtracted signal intensities using the expression: bound/total ODN. The
fraction of ODN bound in each reaction was plotted versus the concentration of albumin.
The data were fit with the following binding equation using GraphPad Prism software to
perform non-linear regression and obtain a value for Kd.
2.2.5 In vitro DC uptake and confocal imaging
DC2.4 cells were cultured with RPMI-1640 supplemented with 10% FBS and 1%
P/S; and were incubated with 1 µM fluorescein-labeled free or lipid-modified CpG A, B,
and C at 37 ℃ for 4 h. After incubation, cells were washed twice with PBS by centrifuge
at 800X g for 5 min prior to flow cytometry quantification. To visualize in vitro cellular
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uptake, DC2.4 cells were cultured and incubated again under the same experimental
conditions and were subjected to confocal imaging by Zeiss LSM 510 microscope.
2.2.6 In vitro TLR reporter cells stimulation
HEK-Blue™-mTLR9 and RAW-BlueTM cells were purchased from InvivoGen and
were used to evaluate CpG ODN’s adjuvant activities in vitro. 0.5µM CpG formulations
were added to InvivoGen HEK-Blue™ murine TLR9 or RAW-Blue™ mouse macrophage
reporter cell lines, both of which are engineered with secreted embryonic alkaline
phosphatase (SEAP) reporter system. After 24h incubation, SEAP levels were quantified
by developing supernatant with QuantiBlue™ substrate for 1h and reading absorption at
620 nm, following the manufacturer’s instructions.
2.2.7 In vitro Bone Marrow Dendritic Cells stimulation
Bone marrow-derived dendritic cells (BMDCs) were generated by following the
previous protocol, with minor changes.29 Briefly, bone marrow was flushed from femurs
and tibia of C57BL/6 mice (5-6 weeks) and plated at 5×105 cells/ml in complete RPMI
plus 5ng/ml recombinant murine GM-CSF. On day 3 and day 5, half of the culture volume
was replaced with fresh complete RPMI + GM-CSF. On day 8, BMDCs were harvested
and were stimulated with 0.5µM immunostimulatory CpG ODNs for 24h. The inflammatory
cytokines secreted by BMDCs, including IL-6, IL-12, and TNF-α, were measured by
ELISA (enzyme-linked immunosorbent assay).
2.2.8 Lymph node imaging and cellular uptake
Groups of C57BL/6 (n=4 Lymph nodes/group) were injected subcutaneously at the
tail base with 3nmol of fluorescein-labeled free CpG or lipo-CpG of class A, B, or C. After
24h, animals were sacrificed and inguinal and axillary LNs were excised and imaged
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using In-Vivo Xtreme (Bruker) imaging system. LNs were then digested with 1.5mL of
freshly prepared enzyme mixture comprised of RPMI-1640 containing 0.8mg/mL
Collagenase/Dispase (Roche Diagnostics) and 0.1mg/mL DNase (Roche Diagnostics)
and LN cells were stained with antibodies against F4/80 and CD11c versus CpG
fluorescence in viable cells. Percentages of CpG+ cells in the LNs were determined by
flow cytometry.
2.2.9 In vivo immunization with immunostimulatory ODN
C57BL/6 mice (6-8 weeks) were vaccinated by a homologous prime-boost
regimen: animals were primed on day 0 and boosted on day 14 (unless stated otherwise)
with 10µg Ovalbumin and 1.24nmol CpG (in unmodified or in lipid-modified forms)
dissolved in PBS. The volume of all vaccine injections was 100 µL/animal. All injections
were performed subcutaneously at the base of the tail.
2.2.10 Tetramer Staining
Seven days after the final immunization, blood samples were collected. Red blood
cells were lysed by ACK lysing buffer. Cells were then blocked with Fc-blocker (antimouse CD16/CD32 monoclonal antibody) and stained with SIINFEKL loaded
phycoerythrin-labeled tetramers (Beckman Coulter) and anti-CD8-APC (ebioscience) for
30min at 4oC. Cells were washed twice, resuspended in FACS buffer, and analyzed on
Attune Focus flow cytometer. Analysis typically gated on live CD8+, Tetramer positive
cells.
2.2.11 ELISA for OVA-Specific IgG
Mice blood samples were collected. Serum anti-OVA IgG levels were determined
by ELISA: 96-well plates were coated overnight with 10μg/ml OVA in PBS and blocked
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with 1% BSA in PBS. After incubation of serum samples for 1h at a series of dilutions,
plates were washed with PBS/1% Tween-20. Goat anti-mouse IgG conjugated to
Horseradish peroxidase (HRP) was added at 1 μg/ml for 30min. Plates were washed with
PBS/1% Tween-20 and ELISA was developed by (3,3’,5,5’-Tetramethylbenzidine) (TMB,
ebioscience). The reaction was stopped by 1M H2SO4 and the absorbance was read at
450 nm and 570 nm using a plate reader.
2.2.12 Statistical analysis
All plots show mean values and error bars represent the SEM. Comparisons of the
mean values of two groups were performed using unpaired Student’s t-tests. One-way
analysis of variance (ANOVA), followed by a Bonferroni post-test was used to compare
>2 groups. *, p<0.05; **, p<0.01; ***, p<0.001; ns, not significant unless otherwise
indicated. Statistical analysis was performed using GraphPad Prism software (San Diego,
CA).
2.3 Results and discussion
2.3.1 Lipid modification enhances phosphodiester CpG ODN’s stability in vitro
The ability of chemical modification to protect oligonucleotides from nuclease
degradation is an important property for efficient immunostimulation. CpG ODN must be
protected from nuclease digestion for maximal activity in vivo. To test whether the lipid
modification improves the ODN’s stability, all three classes of CpG ODNs were incubated
with DNase I at 37 °C. CpG A contains a core sequence with phosphodiester backbone
and a few nucleases resistant phosphorothioate (PS) poly-G blocks at both ends.25
Despite a partial PS backbone stabilization, CpG A ODN is still susceptible to nuclease
degradation, as shown by the complete disappearance of the CpG band illustrated in the
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gel-electrophoresis 16 hours after incubation (Figure 2-1 (a)). However, 5’-lipid
conjugation protects the CpG A ODN from DNase I degradation, showing a nearly intact
band after 24h incubation (Figure 2-1 (a)). The stability of full phosphorothioate CpG B
and CpG C ODN were unaffected in the presence of DNase I (Figure 2-1 (b) and (c)).
Thus, lipid conjugation does not further improve its enzymatic stability.

Figure 2-1. (a-c), CpG A, B, C, and their lipid conjugated formulations were
incubated with DNase I and their stability were analyzed using incubation times of 1, 2,
3, 15, and 21 hours. (d-f), Measurement of the albumin binding by gel shift assay. 15
μM of CpG ODNs were incubated with different concentrations of albumin (15, 50, 100,
200, 300, 400, and 600 µM) in PBS for 2 h at 37 °C, sample aliquots were analyzed by
agarose gel electrophoresis. The binding of albumin induces a motility shift in CpG
ODNs.
Covalent conjugation or noncovalent interaction with albumin has been shown to
extend the half-life of shortly-lived oligonucleotides.30 Albumin functions as the main
fatty acid binding protein in extracellular fluids.31 Thus, lipid conjugation might facilitate
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the binding between albumin and CpG ODN and improve their enzymatic stability. We
used a gel mobility shift assay to visualize the interaction between three classes of CpG
ODNs and albumin protein. As shown in Figure 2-1 (d-f), when different classes of CpG
ODNs were titrated with purified albumin protein, unmodified CpG ODN showed sharp
trailing bands only at high albumin concentrations. This is most likely due to the low
affinity, non-specific interaction between the PS backbone modification and albumin
protein.32-35 Phosphorothioate modification of inter-nucleoside linkage is known to
induce non-specific protein binding. The binding was demonstrated to be sequenceand protein-independent and correlated with the extent (number of PS bonds) of the PS
modification. In contrast, lipo CpG ODN bound to albumin protein at low concentration
via the lipid-albumin interaction. We estimated the equilibrium dissociation constant (Kd)
between 75 µM-100 µM for unmodified CpG ODNs.16 These values are consistent with
previous reports but are nearly 1000 times higher than the Kd of lipid-modified CpG (ca.
100 nM).9

Figure 2-2. CpG’s serum stability assayed by agarose gel. 30 µM free or lipid
conjugated CpG A, B, and C (fluorescein labeled at 3’-end) were incubated with or
without 5 µL mouse plasma serum in PBS (1X) with a final volume of 25 µL at 37 °C for
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8h. Samples were subjected to agarose gel electrophoresis and subsequently
photographed under UV.
Similar stability results were obtained when CpGs were incubated with freshly
isolated mouse serum (Figure 2-2). Taken together, these data showed that lipid
modification enhanced the binding between CpG and albumin and improved the CpG’s
stability in vitro.
2.3.2 Lipid modification on CpG enhances cellular uptake

Figure 2-3. Three classes of CpG ODNs and their lipid-modified forms were
incubated with DC2.4 cells for 4 hours at 37 °C. Cells were washed and were subjected
to laser scanning confocal microscopy imaging for intracellular distribution (a) showing
representative class B CpG and flow cytometry analysis for quantification of cellular
uptake (b). Scale bar: 10 μm. Data show the mean values ± SEM. *, p < 0.05; **, p <
0.01; ***, p < 0.001; ****, p < 0.0001 by one-way ANOVA with Bonferroni post-test.
The accumulation of FAM-labeled CpG ODNs and their lipophilic conjugates in
DC2.4 cells was measured using flow cytometry and confocal microscopy after 4 hours
of incubation with the corresponding CpGs. As expected, DC2.4 cells (a murine dendritic
cell line) treated with 1µM lipid-modified CpG showed a 2~5-fold increase than their
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unmodified counterpart after 4h incubation, independent of CpG type (Figure 2-3). Flow
cytometry analysis suggested that class B and C CpG ODNs exhibited higher cellular
fluorescence compared with CpG A (Figure 2-3 (b)), possibly because of their improved
enzymatic stability. Confocal microscopy analysis showed

similar intracellular

distributions of free CpG and lipo CpG for all three classes, most of which were confined
in intracellular membrane structures, including endosomes, where TLR9 is expressed.
Thus, we confirmed that in vitro, lipid modification greatly enhanced the uptake of CpG
ODNs but did not alter their intracellular distributions.
2.3.3 Adjuvant activities of lipid-modified CpG in vitro

Figure 2-4. Three classes of CpG ODNs and their lipid-modified forms (1 μM) were
incubated with HEK mTLR9 cells, which secrete SEAP upon TLR9 stimulation (a) or RawBlue mouse macrophage reporter cells, which secrete SEAP upon multiple TLR, NOD or
Dectin-1 stimulation (b), SEAP levels were quantified by incubating supernatant with
QuantiBlue substrate for 1 h and reading absorption at 620 nm. (c-e), Bone-marrow-
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derived immature dendritic cells were incubated overnight with 0.5 µM of CpG
formulations, the inflammatory cytokines secreted by BMDCs, including IL-12 (c), IL-6 (d)
and TNF-α (e), were measured by ELISA (enzyme-linked immunosorbent assay). Data
show the mean values ± SEM. *, p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001;
ns, not significant by one-way ANOVA with Bonferroni post-test.
The adjuvant activities of the lipid-modified CpG were first examined in vitro.
Murine TLR9 reporter cells, which were co-transfected with murine TLR9 gene and an
inducible SEAP (secreted embryonic alkaline phosphatase) reporter gene, were
incubated with lipid-modified CpG ODNs, using their unmodified counterparts as controls.
CpG A induced a low but detectable level of TLR9 stimulation in murine TLR9 cells
(Figure 2-4 (a)). Lipid-modified CpG A significantly enhanced the TLR9 stimulation
(Figure 2-4 (a)), as shown by increased SEAP production at 500nM CpG for 24h
incubation, suggesting lipid conjugation does not compromise the TLR9 stimulation for
class A CpG. However, it is believed the accessibility of 5’-terminal of B and C class CpG
oligonucleotide is important for receptor recognition and subsequent immune
stimulation.36 Chemical modification on 5’ terminal thus has been shown to abrogate B
class CpG’s stimulatory activities in vitro.37 Consistent with the previous report, the
immune stimulatory activities of the lipid-modified class B and C CpG ODNs were
significantly reduced when compared with SEAP secretion induced by the unmodified
CpGs (Figure 2-4 (a)). The CpG type-dependent immune modulation was also
demonstrated in RAW-BlueTM mouse macrophage reporter cells (Figure 2-4 (b)), which
secreted SEAP upon multiple TLRs, NOD or Dectin-1 stimulation. TLR stimulation is
known to stimulate DC to produce higher levels of multiple cytokines which directly impact
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DC function.38 The ability of lipo CpG to induce the production of inflammatory cytokines
such as IL-12, IL-6 and TNF-α were evaluated in bone marrow-derived dendritic cells
(BMDCs). Following incubation, CpG A-induced an elevated level of the TNF-α but not
IL-12 and IL-6 (Figure 2-4 (c-e)). The lipid-modified CpG A potentiated the TNF-α
production as compared to unmodified CpG A. However, lipid modification on CpG A had
no effect on IL-12 and IL-6 levels (Figure 2-4 (c-e)). Like the TLR reporter cell results,
lipid modification on class B and C CpG ODNs reduced the IL-12, IL-6 and TNF-α
production by 2-3-fold, though all the cytokines were still detectable (Figure 2-4 (c-e)).
Together, these data demonstrated that lipid modification modulated CpG immune
activities in a CpG class dependent manner. Lipid modification augmented the adjuvant
activity of CpG A but compromised that of class B and C CpG in vitro.
2.3.4 Lipid-modified CpG accumulates in LNs and abrogates CpG-induced toxicity
in vivo
Lipid-modified CpG binds to albumin and accumulates in draining lymph nodes
after s.c. injection.2 Such site-specific accumulation also reduces the systemic exposure
of CpG. Systemic exposure of CpG ODN is known to generate non-specific immune
activation, characterized by lymphocyte proliferation in the spleen and release of
proinflammatory cytokines.39 The lymph node accumulation of all three classes of CpGs
and their lipid conjugates were tested in C57BL/6 mice. Mice were injected with
fluorescein-labeled CpG in original or in lipid-conjugated forms. 24h post-injection, both
inguinal and axillary lymph nodes were isolated and imaged. Both lipo CpG B and lipo
CpG C showed dramatically enhanced accumulation in inguinal and axillary nodes
(Figure 2-5 (a-b)) when compared with class B and C CpG ODNs, respectively. In
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contrast, the overall accumulation of lipo CpG A and CpG A remained low and no
statistical difference was observed between these two groups (Figure 2-5 (a-b)). To
determine the immune cell uptake of CpG, lymph nodes were digested, and cells were
analyzed by flow cytometry after antibodies staining to identify the specific immune cells.
Unmodified CpGs exhibited less uptake in CD11c+ DCs and F4/80+ macrophages, the
key antigen presentation cells in the lymph nodes. In contrast, lipid modification enhanced
the cellular uptake by 2-4 folds, though some fluctuations were observed in the inguinal
nodes in mice injected with class A CpG (Figure 2-5 (c-e)). Overall, these results clearly
showed lipid modification on CpG ODNs enhanced their lymph node accumulation and
immune cell uptake. Among these three types of CpG ODNs we tested, lipo CpG A
exhibited a modest enhancement in lymph node retention. This might be explained by
relatively low stability of class A CpG in vivo. In contrast, lipid modification dramatically
increased the lymph node accumulation of PS backbone-stabilized class B and C CpG.
To test whether lipid modification could reduce the systemic toxicity of CpG, mice
received 3 injections of CpG (1.24 nmol on day 0; 2.48 nmol each on day 2 and day 4)
and their spleens were excised and analyzed for splenomegaly, a common feature of
CpG ODN driven systemic immune activation in mice. Neither CpG A nor lipo CpG Ainduced splenomegaly, showing spleen weights indistinguishable from PBS control
(Figure 2-5 (f)). Mice injected with CpG B induced a nearly 1.5-fold increase in spleen
weight, indicating a systemic exposure of CpG B.2,39 However, lipid modification on class
B CpG ODN markedly alleviated the acute splenomegaly in mice, suggesting a minimized
systemic exposure of class B CpG ODN after lipid modification (Figure 2-5 (f)).
Interestingly, both free CpG C and lipo CpG C treated mice showed no noticeable sign of
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splenomegaly when contrasted with the effect of class B CpG ODN (Figure 2-5 (f)),
suggesting this type of CpG could be safer than CpG B in mice. This data was consistent
with previous findings that lipid conjugated CpG ODNs accumulated in the draining lymph
nodes and reduced systemic exposure.2

Figure 2-5. Mice (n=4 lymph nodes/group) were injected s.c. at the tail base with
3.3 nmol fluorescein-labeled class A, B, and C CpG or lipo-CpG. Inguinal LNs (proximal
nodes) and axillary LNs (distal nodes) were isolated 24 hours post-injection and CpG
accumulation in nodes was imaged (a) and quantified (b) by using In-Vivo Xtreme (Bruker)
imaging system. (c-e), lymph nodes were digested, and lymph nodes cells were stained
with DAPI and antibodies against F4/80, CD11c. Shown are representative flow cytometry
plots of CD11c staining and F4/80 staining (c) versus CpG fluorescence in viable (DAPI-)
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cells. Percentages of CpG+ cells in the LNs determined by flow cytometry at 24 hr (d, e).
(f), Splenomegaly in mice (n=3/group) assessed on day 6 after 3 injections of CpG (1.24
nmol on d0, 2.48 nmol each on d2 and d4). Data show the mean values ± SEM. *, p <
0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001; ns, not significant by one-way ANOVA
with Bonferroni post-test.
2.3.5 Lipid modification on class B and C CpG ODNs, but not on class A CpG
ODN, dramatically enhance immunogenicity of molecular vaccines

Figure 2-6. C57Bl/6 mice (n=4/group) were immunized with ovalbumin (10 µg) +
CpG (1.24 nmol) on d0 and d14. Six days after the final immunization, mice were bled
and antigen-specific T-cell responses in peripheral blood were evaluated by SIINFEKL
tetramer assay. Shown are representative flow cytometric dot plots of H-2Kb/SIINFEKL
tetramer staining of CD8+ cells (a) and quantification (b). (c), at d 20, serum samples
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were collected and assayed by ELISA for anti-OVA IgG production. Data show the mean
values ± SEM. *, p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001; ns, not significant
by one-way ANOVA with Bonferroni post-test.
The in vivo activities of lipid-modified CpG ONDs as vaccine adjuvants were
evaluated in C57BL/6 mice. CpG ODN has been widely studied to improve both humoral
and cellular immune responses in animals.10,16,17 Mice were immunized subcutaneously
on day 0 and day 14 with 10μg Ovalbumin (OVA) protein antigen adjuvanted by 1.24nmol
CpG ODNs in original or in lipid conjugates formulations. OVA was simply mixed with
CpG ODNs and was not associated with CpG or lipo-CpG. No OVA-specific CD8+ T cells
and anti-OVA IgG antibody above the baseline were detected in mice immunized with
class A CpG (Figure 2-6).
Despite the enhanced serum stability as well as TLR9 stimulation in vitro, lipidmodified CpG A did not enhance the frequency of OVA-specific CD8+ T cells in blood,
showing an average of 5.4% comparable with those with OVA alone. However, in mice
immunized with lipo CpG B or lipo CpG C, nearly 16% and 22% of the blood CD8+ T cells
were specific for the MHC-I-restricted peptide OVA257-264, respectively (Figure 2-6 (a-b)).
These frequencies were markedly improved when compared to mice immunized with
unmodified class B and C CpG ODNs. These results were in contrast with the stimulatory
activities of lipo CpG B and lipo CpG C in vitro, where a 2-3-fold reduction of activities
was observed. Furthermore, lipo CpG B and lipo CpG C rapidly potentiated the
development of an OVA-specific IgG response as compared to their unmodified
counterpart (Figure 2-6 (c)). In mice immunized with OVA together with CpG A or lipo
CpG A, no increase in OVA-specific IgG was seen compared with mice immunized with
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OVA alone. We thus concluded that lipid modification on CpG B and CpG C, but not on
CpG A, efficiently enhanced CD8 T cell and B cell responses to a protein antigen in vivo.
Unmethylated cytosine-phosphate-guanosine (CpG) dinucleotide is recognized by
TLR9 and induces immune system activation.12-14 Immunostimulatory activities of CpG
were first discovered when a DNA from Bacille Calmette-Guerin was found to stimulate
the production of type I interferon.29 Since then, synthetic immunostimulatory
oligonucleotides containing CpG motifs have been widely used as vaccine adjuvant
because these ODNs were stable against enzymatic digestion, and were capable of
stimulating a wide variety of immune cells.10,16,17 To date, however, the in vitro promise of
CpG has not been translated to in vivo primarily due to limited therapeutic efficacy and
safety concerns.17 When used as a vaccine adjuvant, CpG must reach LNs, the anatomic
site where all the immune cells interact with each other. Attempt to enhance the lymph
node delivery of CpG has included the nanoparticulate materials.23,24 However, it remains
difficult to design nanocarriers which meet all the criteria for in vivo LNs targeting.40,41
Most of the current nanoparticles do not fulfill clinical demands primarily due to
requirements for complex designs including surface engineering to reduce non-specific
tissue interactions, structural modification to enhance CpG encapsulation and incorporate
ligands to maintain immune cells targeting.41 Possible stability, toxicological issues also
restrict the nanocarrier’s clinical application in the short-term.42-44 Thus, a molecular
approach would be more attractive.
Previously we developed a lipo CpG conjugation approach which targeted the CpG
to the draining LNs via an albumin-mediated mechanism.2 Structurally optimized lipo CpG
conjugate binds to endogenous albumin and subsequently transports to the draining LNs.
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Albumin binding dramatically increased CpG ODN’s hydrodynamic size, prevented it from
diffusing into blood circulation, and retargeted it to the lymphatics. However, only class B
CpG was investigated. CpG ODNs have been divided into three major classes (A, B and
C types) based on their sequences, structural characteristics and immunological activities,
so it is important to evaluate the immunostimulatory activities of each CpG class after lipid
modification. Although additional classes of immunostimulatory ODNs have been
described, of great interest are the recently discovered P-type and S-type ODNs which
have been recently discovered and not been utilized extensively. The present study
describes in vitro and in vivo immunostimulatory activities of three representative
sequences derived from different types of CpG ODNs after lipid modification. Lipid
modification at 5’-end of all three classes of CpG greatly enhanced their cellular uptake
in vitro. Class A CpG, which contains palindromic CpG phosphodiester sequences with
phosphorothioate G-rich ends, lacks the stability in vitro and in vivo. Subsequent lipid
conjugation enhanced class A CpG’s stability and immunostimulatory activities in vitro.
However, the ability of class A CpG to boost the humoral and cellular immune responses
in vivo remains limited, as no potent immune responses were observed in both
unmodified and lipid conjugated class A CpG ODNs when combined with a protein
antigen. Outstanding responses to antigen have been reported in a variety of studies
using class B CpG as an adjuvant.10,16,17 Our results demonstrated that lipid modification
on both class B and C CpG, contrasted with class A CpG, acted as very potent TH-1promoting adjuvants in mice, although lipid modification appeared to greatly compromise
their immunostimulatory activities in vitro. The observed difference between the activities
in vitro and in vivo might be explained by increased LN accumulation and APC uptake in
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vivo, however, current studies cannot rule out the existence of other mechanisms
independent of lymphatic system targeting. One possible explanation could be CpG
adjuvant’s kinetic in terms of LN accumulation. Interestingly, despite dramatic increases
in antigen-specific CD8+ T cells and antibody responses, repetitive injection of class C
CpG into mice did not induce splenomegaly, one of the major side effects associated with
systemic immune activation by CpG. Similar abrogation of systemic toxicity was observed
in lipid-modified class B and C CpG ODNs, suggesting lipid modification was an effective
approach to simultaneously improving the efficacy and safety of CpG in vaccines.
2.4 Conclusions
Overall, we have confirmed that lipid conjugated CpG ODNs are potent adjuvants
in vivo. Our findings strongly suggest that in vivo adjuvant properties of CpG do not
correlate with activities in vitro, highlighting the importance of lymphatic targeting in
vaccines. Our study extends recent work on CpG as an adjuvant by demonstrating that
targeting APCs in LN is the key to potentiating adjuvant activities of CpG ODN in vivo.
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CHAPTER 3 TARGETING SUPPRESSIVE ODN TO LYMPH NODES INHIBITS TLR9MEDIATED ACTIVATION OF ADAPTIVE IMMUNITY
3.1 Introduction
TLRs are highly conservative transmembrane receptors which are critical factors
for early detection of foreign pathogens and following initiation of adaptive immune
responses.45,46 TLRs recognize specific PAMPs associated with microbial pathogens, as
well as a number of endogenous ligands such as self-protein, lipids, and nucleic acids.45,46
Other than pathogen sensing and clearance, much research reveals that endogenous
ligand-mediated signaling through TLR is closely related to the pathogenesis of various
autoimmune diseases,47-53 such as systemic lupus erythematosus (SLE)50 and
rheumatoid arthritis (RA)52. In particular, TLRs sensing intracellular nucleic acid, such as
TLR9, play a pivotal role in the activation of autoimmune pathology.51 For example, under
certain conditions, TLR9 recognized and sensed self-DNA, leading to the activation of Band T-cells and production of proinflammatory cytokines.53 Such unrestrained infectious
or self-pathogen DNA-induced immune activation can cause tissue damage, resulting in
the development of autoimmune diseases such as RA. 52,53 Targeting antagonists which
suppress TLR-mediated immune responses to corresponding TLR receptors may be
effective in improving the therapeutic efficacy of autoimmune diseases.47,49,54
It was found that activated immune cells were restrained from secreting proinflammatory and TH-1-promoting cytokines once they were exposed to telomeric DNA
containing repetitive TTAGGG motifs.55-57 Synthetic ODNs containing repetitive TTAGGG
motifs which mimic mammalian telomeric sequence can neutralize bacterial DNA-driven
immune activation.55,58 These suppressive ODNs (Sup-ODNs) can act on dendritic cells
and macrophages, leading to inhibition of B- and T-cells activation and differentiation.58
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In several disease models, Sup-ODNs were proved to reduce the level of autoimmunemediated stimulation and modulate progression of diseases.58,59 These beneficial effects
of Sup-ODNs are characterized by inhibition of antigen-specific cellular and humoral
immune responses as well as downregulation of proinflammatory cytokines.47,58,60
However, immune suppression and therapeutic benefits were achieved at relatively high
ODN concentrations.60 Such high-dose treatment can cause serious side effects which
limit clinical application of Sup-ODNs.61,62 In chronic autoimmune diseases such as RA,
draining LNs are emerging as therapeutic targets for immune modulation. 63 Housing a
large portion of APCs and lymphocytes, LNs specialize in antigen presentation, defining
the immunological fates of T- and B-cell responses.11 Since Sup-ODNs act on APCs, we
hypothesize that approaches targeting Sup-ODNs to APCs in the draining LNs can
intensify the Sup-ODN-mediated immune suppression, enabling possible dose-sparing
manner in the treatment of autoimmune diseases.
We have developed an ‘albumin-hitchhiking’ approach which uniquely targets
synthetic ODNs to APCs in the LNs.2 In this approach, ODNs were conjugated to an
albumin-binding diacyl lipid at the 5’-terminal and subsequently accumulated in the
draining LNs via hitchhiking endogenous albumin after subcutaneous injection.2 The
efficacy of this approach depends on a structural and molecular design that hijacks traffic
route of endogenous albumin in the interstitial fluid: following subcutaneous injection, lipo
ODNs bind avidly to albumin, and transport to draining LNs via lymphatic capillary, and
accumulate considerably in LN-resident APCs. This approach simultaneously improves
an immunostimulatory ODN’s adjuvant efficacy and safety by confining the ODN in the
draining LNs, restraining it from systemic dissemination.2 We hypothesize that the
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efficacy of immunosuppressive ODNs can be substantially improved by targeting them to
LNs where a large portion of APCs reside. Here we evaluated inhibitory properties of a
lipid-modified suppressive ODN in vitro and in vivo. Our results revealed that in vitro, lipidmodified Sup-ODN encoding repetitive TTAGGG motif enhanced cellular uptake while
showed similar inhibitory efficacy as unmodified ODN in TLR9-mediated activation. In
vivo, subcutaneous injection of a low dose of lipo Sup-ODN led to increased accumulation
in APCs in draining LNs and dramatically suppressed TLR9 agonist-adjuvanted humoral
and cellular immunity. Collectively, our findings indicated that LN-targeting of Sup-ODN
via lipid modification may be a promising approach to potentiate immunoinhibitory
properties of Sup-ODN and thus might be applicable for the control of TLR9-mediated
immune activation.
3.2 Materials and methods
3.2.1 Materials
All reagents for DNA synthesis were purchased from Glen research (Sterling, VA)
or Chemgenes (Wilmington, MA) and used following the manufacturer’s instructions. 3’Fluorescein amidite (FAM) labeled controlled pore glass was purchased from Allele
Biotechnology (San Diego, CA). Fatty acid-free BSA was purchased from Sigma-Aldrich.
Ovalbumin protein was purchased from Worthington Biochemical Corporation (Lakewood,
NJ). Murine MHC class I tetramer was obtained from MBL international Corporation
(Woburn, MA). Antibodies were purchased from eBioscience (San Diego, CA) or BD
Bioscience (San Jose, CA). All other reagents were from Sigma-Aldrich and used as
received except where otherwise noted.
3.2.2 Animals and cells
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Animals were housed in the USDA-inspected WSU Animal Facility under federal,
state, local and NIH guidelines for animal care. Female C57BL/6 mice (6-8 weeks) were
obtained from the Jackson Laboratory. RAW-Blue™ and HEK-Blue™-mTLR9 reporter
cell lines were purchased from InvivoGen (San Diego, California). Cells were cultured in
complete medium (DMEM, 10% fetal bovine serum (Greiner Bio-one), 100 U/mL penicillin
G sodium and 100μg/mL streptomycin (Pen/Strep), DMEM sodium pyruvate (1mM) and
20μM β-mercaptoethanol (β-ME)).
3.2.3 Synthesis of diacyl lipid phosphoramidite
The diacyl lipid phosphoramidite was synthesized as previously described. 2 A
solution of stearoyl chloride (6.789 g, 22.41 mmol) in 1,2-dichloroethane (50 mL) was
added dropwise to a solution of 1,3-diamino-2-dydroxypropane (1.0 g, 11.10 mmol) in the
presence of 1,2-dichloroethane (100 mL) and triethylamine (2.896 g, 22.41 mmol). The
reaction mixture was stirred for 2 h at 25 °C and then heated at 70 °C overnight. The
reaction mixture was then cooled to 25 °C, filtered, and the solid was sequentially washed
with CH2Cl2, CH3OH, 5% NaHCO3 and diethyl ether. The product was dried under
vacuum to give the intermediate product as a white solid (yield: 90%). 1H NMR (300 MHz,
CDCl3, ppm): δ 6.3 (m, 2H), 3.8 (m, 1H), 3.4-3.2 (m, 4H), 2.2 (t, 4H), 1.6 (m, 4H), 1.3-1.2
(m, 60H), 0.9 (t, 6H). The intermediate product (5.8g, 9.31mmol) and N, NDiisopropylethylamine (DIPEA, 4.2mL, 18.62mmol) was then suspended in anhydrous
CH2Cl2 (100mL). The mixture was cooled on an ice bath and 2-Cyanoethyl N, Ndiisopropylchlorophosphoramidite (8.6 mL, 0.47 mmol) was added dropwise under dry
nitrogen. After stirring at 25 °C for 1 h, the solution was heated to 60 °C for 90 min. The
solution was washed with 5% NaHCO3 and brine, dried over Na2SO4 and concentrated
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under vacuum. The final product was isolated by precipitation from cold acetone to afford
4 g (55% yield) lipid phosphoramidite as a white solid. 1H NMR (300 MHz, CDCl3): δ 6.4
(m, 2H), 3.9 (m, 2H), 3.8 (m, 2H), 3.6 (m, 2H), 3.0-2.9 (m, 2H), 2.6 (t, 2H), 2.2 (m, 4H),
1.6 (m, 6H), 1.3-1.2 (m, 72H), 0.9 (t, 6H). 31P NMR (CDCl3): 154ppm.
3.2.4 Synthesis and purification of oligonucleotides
Both lipid-modified and free Sup-ODN were synthesized on a 1.0 micromole scale
using an ABI 394 synthesizer. Diacyl lipid phosphoramidite was conjugated as a final
‘base’ on the 5’ end of oligos. Lipid phosphoramidite was coupled using the DNA
synthesizer as previously described.2 After the synthesis, ODNs were cleaved from the
solid support, deprotected, and purified by reverse phase HPLC using a C4 column
(BioBasic-4, 200 mm x 4.6 mm, Thermo-Scientific). A gradient of 20-60% (buffer B) in 10
min, was used for the unmodified ODN purification and for lipid-modified ODN, the
gradient was set at 50-80% (Buffer B) for 10 min and 80-100% for 5 min. Buffer A:
triethylammonium acetate (TEAA, 0.1 M, pH 7.0), buffer B: Methanol. Lipophilic ODNs
typically eluted at 12 min while unconjugated oligos eluted at 5 min. Fluorescein label
ODNs were synthesized using 3’-(6-Fluorescein) tagged controlled pore glass purchased
from Chemgenes. Lipid-conjugated Sup-ODN (ODN A151: 5'-ttagggttagggttagggttagggt
-3’)55 and CpG ODN 1826 (CpG B ODN: 5’-tccatgacgttcctgacgtt-3’)64 were synthesized
by the above method and characterized by Mass Spec. All ODN sequences were
modified by phosphothioation to improve stability against nuclease degradation.
3.2.5 In vitro DC uptake and confocal imaging
DC2.4 cells were cultured with RPMI-1640 supplemented with 10% FBS and 1%
P/S, and were incubated with 1 µM FAM-labeled free or lipid-modified Sup-ODN at 37 ℃
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for 12 h. After incubation, cells were washed twice with 1 x PBS by centrifuge at 800X g
for 5 min prior to flow cytometry quantification. To visualize in vitro cellular uptake, DC2.4
cells were cultured and incubated again under the same experimental conditions and
were subjected to confocal imaging by Zeiss LSM 510 microscope.
3.2.6 In vitro TLR reporter cells stimulation
HEK-Blue™-mTLR9 and RAW-BlueTM cells were purchased from InvivoGen and
were used to evaluate Sup-ODN’s inhibitory activities in vitro. In a typical procedure, 500
nM CpG ODN 1826 and 1.5 μM Sup-ODN were added to InvivoGen HEK-Blue™ murine
TLR9 or RAW-Blue™ mouse macrophage reporter cells, both of which are engineered
with secreted embryonic alkaline phosphatase (SEAP) reporter gene. After incubating for
24 h, SEAP levels were quantified by developing supernatants with QuantiBlue™
substrate for 1 h and reading absorption at 620nm, following manufacturer’s instructions.
3.2.7. LNs imaging and cellular uptake
Groups of C57BL/6 mice (n=4 LNs/group) were injected subcutaneously at the tail
base with 3.3 nmol of FAM-labeled free or lipid-modified Sup-ODN. After 24 h, animals
were sacrificed and inguinal and axillary LNs were excised and imaged using In-Vivo
Xtreme (Bruker) imaging system. LNs were then digested with 1.5 mL freshly prepared
enzyme mixture comprised of RPMI-1640, 0.8 mg/mL Collagenase/Dispase (Roche
Diagnostics) and 0.1 mg/mL DNase (Roche Diagnostics). LNs cells were stained with
antibodies against F4/80 and CD11c versus ODN fluorescence in viable cells.
Percentages of ODN positive cells in the LNs were determined by flow cytometry.
3.2.8 In vivo tolerization with lipo ODN A151
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C57BL/6 mice (6-8 weeks; n=3 per group) were tolerized with PBS, 1.24 nmol of
free or lipo-Sup ODN on day 0. On day 3, mice were immunized with 3.72 nmol CpG 1862
ODN plus 10 µg OVA. On day 10, blood was collected from mice and OVA-specific
immune responses were evaluated. The same mice were tolerized once again as
previously on day 14 and three days later, a boost injection of 1.24 nmol lipo-G2-CpG
ODN 1826 2 plus 10 µg OVA was injected into each animal. Blood samples were collected
on day 24 to analyze the cellular and humoral anti-OVA immune responses. The volume
of all vaccine injections was 100 µL/mouse. All injections were performed subcutaneously
at the base of the tail.
3.2.9 Tetramer staining
Seven days after challenge, blood samples were collected, and red blood cells
were lysed by ACK lysing buffer. Cells were then blocked with Fc-blocker (anti-mouse
CD16/CD32 monoclonal antibody) and stained with SIINFEKL loaded phycoerythrinlabeled tetramer (Beckman Coulter) and anti-CD8-APC (ebioscience) for 30min at room
temperature. Cells were washed twice, resuspended in FACS buffer, and analyzed on
Attune Focus flow cytometer. Analysis typically gated on live CD8+, Tetramer positive
cells.
3.2.10 Intracellular cytokine staining
Peripheral blood was lysed with ACK buffer and washed with PBS twice. Purified
cells were seeded in 96-well round-bottomed plates and pulsed with 10 μg/mL OVA
peptide SIINFEKL for 2 h at 37 °C in T-cell media (RPMI-1640, 10% FBS, 50 μM βmecaptoethanol, 1% P/S), followed by the addition of brefeldin A for 4 hours. Cells were
stained with anti-CD8-APC and then fixed using Cytofix following the manufacturer’s
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instructions. Next, cells were washed and permeabilized. Intracellular staining for antiIFN-γ-PE and anti-TNF-α-FITC was performed following the manufacturer’s instructions
and cells were analyzed by Attune Focus flow cytometer.
3.2.11 ELISA for OVA-specific IgG
Mice were bled, and blood samples were collected. Serum anti-OVA IgG levels
were determined by ELISA: 96-well plates were coated overnight with 10 μg/ml OVA in
PBS and blocked with 1% BSA in PBS. After incubation of serum samples for 1h at a
series of dilutions, plates were washed with PBS/1% Tween-20. Goat anti-mouse IgG
conjugated to Horseradish peroxidase (HRP) was added at 1 μg/ml for 30 min. Plates
were washed with PBS/1% Tween-20 and ELISA was developed by (3,3’,5,5’Tetramethylbenzidine) (TMB, ebioscience). The reaction was stopped by 1 M H2SO4 and
the absorbance was read at 450 nm and 570 nm using a plate reader.
3.2.12 Statistical analysis
All plots represent mean values and error bars represent the standard error of the
mean (SEM). Comparisons of the mean values of two groups were performed using
unpaired Student’s t-tests. One-way analysis of variance (ANOVA), followed by a
Bonferroni post-test, was used to compare >2 groups. *, p<0.05; **, p<0.01; ***, p<0.001;
ns, not significant unless otherwise indicated. Statistical analysis was performed using
GraphPad Prism 6 software (San Diego, CA).
3.3 Results and discussion
3.3.1 Lipid functionalization of ODN A151 enhances the cellular uptake in vitro
Synthetic ODN A151 containing TTAGGG motif repeats has been shown to inhibit
TLR9 signaling and attenuate a variety of inflammatory responses.55 To target ODN A151
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to the APCs in LNs through the “albumin-hitchhiking” approach, we functionalized A151
at the 5’-terminal with a diacyl lipid (lipo-A151) as an albumin binding domain.
Hydrophobic modification of ODNs such as antisense oligos and siRNA has been shown
to be an effective approach to enhance their cellular uptake.65,66

Figure 3-1. (a) DC 2.4 cells were incubated with 1 μM of free A151 or lipo-A151
for 12 h at 37 °C. Cells were washed and then subjected to laser scanning confocal
microscopy imaging for intracellular distribution. Representative confocal images of cells
treated with A151 (top panels) and lipo-A151 (bottom panels). Scale bar: 20 μm. (b)
Flow cytometry analysis for quantification of cellular uptake. Data show the mean values
± SEM. *, p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001 by unpaired two-tailed ttest.
To test whether lipid modification alters cellular uptake and intracellular distribution
of ODN A151, we incubated DC2.4 cells with fluorescein-tagged lipo-A151, using
unmodified ODN A151 as a control. DC2.4 cells treated with lipo-A151 exhibited
significantly enhanced cellular uptake when compared with unmodified ODN A151
(Figure 3-1), as showed by flow cytometry and confocal microscopy analysis. Like our
previous results, lipid-modified ODN preferentially accumulated in intracellular membrane
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structures.2,66 In vitro, lipid modification promotes quick membrane association and
following cellular internalization by a mechanism similar to endocytic pathways. In
contrast, unmodified ODN A151 alone demonstrated less cellular uptake in DC2.4 cells,
indicating plasma membrane permeability of unmodified ODN A151 was restricted by the
negatively charged nature of oligonucleotide following exposure to dendritic cells.
3.3.2 Lipid-modified ODN A151 inhibits CpG-induced immune activation in vitro

Figure 3-2. (a) Free A151 or lipo-A151 (1.5 μM) with or without CpG B ODN (500
nM) were co-incubated for 24 h in HEK-TLR-9 reporter cells. Cell activation was quantified
by measuring the SEAP levels in the supernatant. (b) HEK-TLR-9 cells were stimulated
with 500 nM CpG for 3 h first, after which 1.5 μM of free A151 or lipo-A151 were added
to the cells. Cell activation was determined. (c and d) HEK-TLR-9 cells were incubated
with A151, or lipo-A151 for 12 h, after which cells were washed (c), or without a wash (d)
before CpG ODN (500 nM) was added for the TLR-9 stimulation. (e and f) A151 and lipo-
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A151 were co-incubated with imiquimod (TLR-7 agonist) (e) or lipopolysaccharide (LPS)
(TLR-4 agonist) (f) for 24 h in Raw-Blue reporter cells. Data show the mean values ±SEM.
*, p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001; ns, not significant by one-way
ANOVA with Bonferroni post-test.
Modification on immunostimulatory ODNs often influences their biological
functions.2,67 To test whether lipid modification on ODN A151 compromises its inhibitory
activity, the immune suppressive properties of both lipo-A151 and unmodified A151 were
first evaluated in murine TLR9 (mTLR9) reporter cells. HEK-Blue cells transfected with
murine TLR9 and an NF-κB-inducible SEAP (secreted embryonic alkaline phosphatase)
reporter gene were incubated with lipo-A151 or free A151 in the presence of CpG ODN
and the activation of NF-κB was quantified by measuring the SEAP concentrations in the
supernatant. TLR9 reporter cells were activated when stimulated with a class B CpG ODN
(CpG ODN 1826, 500 nM) which specifically bound to mTLR9 (Figure 3-2 (a)). CpGdependent TLR9 stimulation was inhibited by up to 75% following incubation with free
A151 (1.5μM). Residual TLR9 activation was retained in cells treated with free A151,
showing a small but statistically significant increase in SEAP production as compared
with no treatment group (Figure 3-2 (a)). However, the addition of same concentration of
lipo-A151 completely inhibited the CpG ODN induced TLR9 activation in HEK cells
(Figure 3-2 (a)), lowering the SEAP production to the basal level that was statistically
indistinguishable from control levels (Figure 3-2 (a)). The successful inhibition of CpGinduced TLR9 activation required treatment of TLR9 cells with suppressive ODN before
or during the CpG stimulation, as both lipo-A151 and free A151 were unable to reduce
the SEAP production when mTLR9 cells were stimulated with CpG prior to addition of
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suppressive ODN (Figure 3-2 (b)). However, when mTLR9 cells were treated with
suppressive ODN for 3 hours, washed, and then stimulated with CpG ODN, both free
A151 and lipo-A151 were partially effective in the suppression of TLR9 activation (Figure
3-2 (c)). In this case, statistically significant inhibition persisted for lipo-A151, showing
retention of 50% of its inhibitory capacity compared to unmodified A151 (Figure 3-2 (cd)). These findings suggest that instead of compromising the suppressive properties,
lipid-modification on A151 enhances the inhibitory efficacy of TLR9 stimulation. To test
whether lipo-A151 can act broadly to suppress immune activation elicited by other TLR
stimulants,68,69 Raw-Blue cells were used to replace mTLR9 cells as reporter cells in the
above experiments. Raw-Blue cells are stably transfected with SEAP gene and NF-κB
inducible by many pattern-recognition receptors, including Toll-like receptors (except
TLR5) and NOD-like (nucleotide-binding oligomerization domain-like) receptors. In
contrast to inhibition of NF-κB activation by a TLR9 agonist, both lipo-A151 and
unmodified ODN A151 showed little suppressive effect on Raw-Blue cells stimulated by
imiquimod (TLR7 agonist) and LPS (lipopolysaccharide, TLR4 agonist) (Figure 3-2 (e-f)),
respectively, suggesting in these reporter cells, ODN A151 was a TLR9-specific inhibitor.
3.3.3 Lipid-modified ODN A151 accumulates in draining LNs in vivo
Our previous study showed that lipid-modified ODNs accumulated in the LNs
following subcutaneous injection by binding and trafficking with endogenous albumin.2 To
test whether lipid modification results in efficient trafficking of ODN A151 to draining LNs,
we assessed LN accumulation of ODN A151 following subcutaneous injection. C56BL/6
mice were injected subcutaneously with 3.3nmol FAM-labeled free A151 or lipo-A151 at
the tail base and 24 h later, inguinal and axillary LNs were isolated and imaged.
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Consistent with our previous findings, lipid-modified A151 exhibited 10- and 18-fold
increases in inguinal and axillary nodes than unmodified A151, respectively (Figure 3-3
(a-b)). To identify the cells in the LNs that internalized ODN A151, the LNs were digested
and stained with antibodies against F4/80 and CD11c. By flow cytometry, cellular uptake
of lipo-A151 in the draining LNs was highest in APCs, with the majority of lipo-A151
accumulated in CD11c+ DCs and F4/80+ macrophages (Figure 3-3 (c-d)). These cells
were key APCs that specialized in antigen presentation and immune activation. In accord
with the imaging analysis, lipo-A151 showed considerably more uptake in both DCs and
macrophages than free A151. Together, these results confirmed that in vivo, lipid
functionalized A151 efficiently accumulated in the APCs in the draining LNs.

Figure 3-3. Mice (n = 4 LNs/group) were injected s.c. at the tail base with 3.3 nmol
FAM-labeled A151 or lipo-A151. Inguinal LNs (proximal nodes) and axillary LNs (distal
nodes) were isolated 24 h post injection and were imaged (a) and quantified (b) by using
In-Vivo Xtreme (Bruker) imaging system. (c and d) LNs were digested and LNs cells were
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stained with antibodies against F4/80, CD11c. Percentages of A151 ODN positive cells
in inguinal nodes (c) and axillary nodes (d) were determined by flow cytometry at 24 h.
Data show the mean values ± SEM. *, p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p <
0.0001 by unpaired two-tailed t-test.
3.3.4 Lipid-modified ODN A151 inhibits CpG ODN-induced antigen-specific
cellular and humoral responses in vivo
To determine whether LNs targeting suppressive ODN A151 can suppress the
CpG-induced immune responses in vivo, the inhibitory effects of lipo-A151 versus
unmodified A151 on vaccine-induced T- and B-cell responses were evaluated. Naïve
C57BL/6 mice were tolerized with a low dose (1.24nmol) of lipo-A151 or unmodified A151,
by subcutaneous injection at the tail base. Three days later, all the animals were
challenged with a large dose of CpG (3.72nmol) plus 10μg of ovalbumin (OVA). OVAspecific immune responses were determined in the blood on day 10 (Figure 3-4 (a)).
ODN A151 at this dosage had little impact on OVA-specific CD8+ T cells, as similar
frequencies of OVA tetramer+ CD8+ T cells were seen in mice tolerized with unmodified
A151 and PBS (Figure 3-4 (b-c)). In contrast, lipo-A151 treatment notably reduced the
frequency of antigen-specific CD8+ T cells in the blood (Figure 3-4 (b-c)). An identical
tolerization injection was administered on day 14 and three days later, mice were
challenged with 1.24nmol LN-targeting CpG (lipo CpG) mixed with 10μg OVA. As shown
in Figure 3-4 (b) and (d), CD8+ T cell responses after boost were relatively potent in mice
tolerized with PBS or unmodified A151, characterized by 17.5% and 14% tetramerpositive CD8+ T cells in the blood, respectively. However, in mice tolerized with lipo-A151,
less than 5% of CD8+ T cells in blood were OVA-specific. To our knowledge, this is the
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first example where the priming of CD8+ T cells is suppressed to such a low level without
using a global immunosuppressant. Interestingly, at this low (1.24nmol) dose used, both
A151 and lipo-A151 significantly reduced TH-1-biased CD4+ T cells capable of secreting
IFN-γ after antigen re-stimulation (Figure 3-4 (e)). Additionally, we measured the levels
of OVA-specific IgG in the sera of immunized mice to assess the ability of lipo-A151 to
mediate humoral immunity. Sera from immunized mice were collected on day 27 following
the initial treatment. ELISA measurements of serum titers of OVA-specific IgG showed a
significantly lower level of anti-OVA IgG in mice tolerized with lipo-A151 but not
unmodified A151 (Figure 3-4 (f)). Together, these results suggested LN-targeting
suppressive ODN A151 dramatically improved immune suppressive activities that
modulated both the CD8+ T cell- and B cell-mediated immunity.

Figure 3-4. (a) Tolerizing model displays experimental protocol. C57Bl/6 mice
(n = 3/group) were tolerized with PBS, 1.24 nmol of A151, or lipo-A151 on day 0 and day
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14. Mice were challenged with 3.72 nmol CpG ODN plus 10 μg OVA on day 3 and 1.24
nmol lipo-CpG ODN plus 10 μg OVA on day 17. One week after each challenge (day 10
and day 24), blood samples were collected and antigen-specific CD8+ T-cell responses
in peripheral blood were evaluated by SIINFEKL tetramer assay. (b) Representative flow
cytometric plots of H-2Kb/SIINFEKL tetramer staining of CD8+ cells post-prime (upper
panels) and post-boost (lower panels). (c and d) Quantification of SIINFEKL tetramerpositive CD8+ cells in the blood after CpG and OVA antigen prime (c) and boost (d). (e)
Stimulation of white blood cells ex vivo for 6 h in the presence of OVA showed a reduced
response in CD4+ T cells after tolerization using A151 or lipo-A151 compared with PBS.
IFN-γ-secreting CD4+ T cells frequencies were determined by intracellular cytokine
staining. (f) On day 24, serum samples were collected and assayed by ELISA for antiOVA IgG production. Data show the mean values ± SEM. *, p < 0.05; **, p < 0.01; ***, p
< 0.001; ****, p < 0.0001; ns, not significant by one-way ANOVA with Bonferroni post-test.
Enhancing activation of innate immunity and thereby potentiating adaptive immune
responses has long been considered in a clinic in the treatment of cancer, allergy, and
infections.45,46 In parallel with the discovery of CpG ODN in activating TLR9 and inducing
potent antigen-specific immunity, it was found activation of innate immunity through TLR,
such as TLR9, could lead to deleterious immune responses that resulted in the
destruction of self-tissues.47-53 This has sparked the search for specific inhibitors which
could inhibit CpG-mediated activation.47-53 Studies have revealed several structurally
distinct ODNs can differentially modulate TLR9-mediated immune stimulation and
suppress the biological activity of TLR9 ligation.55,58,60,68 In particular, ODNs containing
immunosuppressive motif TTAGGG were recognized for their ability to attenuate
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inflammatory responses in vivo by blocking TLR9 signal pathways.58,68 Administration of
A151 (a representative suppressive ODN with TTAGGG motif) has been shown to inhibit
dendritic cell activation, suppress TH-1 differentiation and support the induction of
regulatory T cells, prevent STAT1 and STAT4 phosphorylation, block cytosolic nucleic
acid sensing pathways.58 However, systemic administration of phosphorothioate ODN is
known to induce side effects including platelet activation, which has limited the clinic
translation of suppressive ODN in humans.61,62
Emerging evidence supports the contribution of LNs in the generation and
perpetuation of autoimmunity resulted from chronic inflammation.11,63 During the
progression of autoimmune diseases such as RA, antigens and inflammatory signals (e.g.,
DNA) resulted from the immune destruction drain into the LNs and aggravate the
pathogenic inflammation.63 Thus, approaches that target and modulate the immune cell
cross-talk and reciprocal interactions within the LNs microenvironment hold great promise
for the treatment of autoimmune inflammation.
We present here the results of our attempt to design and implement an ‘albuminhitchhiking’ approach to locally deliver an immune suppressive ODN to draining LNs to
suppress the TLR9-activation-induced adaptive immune responses. We previously
developed a diacyl lipid-ODN conjugation which uniquely targeted ODNs to APCs in the
LNs via an albumin-mediated transportation.2 Albumin-binding domain increases the
hydrodynamic size of ODN and prevents it from diffusing into blood circulation, retargeting it to the lymphatics where a large portion of APCs reside. In addition to LNs
targeting, lipo-ODN exhibited high affinity toward membrane and accumulated in the
endosome.2,66 We assessed the in vitro and in vivo properties of diacyl lipid-modified ODN
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A151. In vitro, lipo-A151 significantly enhanced the cellular uptake compared with
unmodified A151. Our data are consistent with previous observation where hydrophobic
conjugation on siRNA resulted in the enhancement of cellular uptake.65 We observed that
although co-presence of lipo-A151 and CpG was most effective at inhibiting TLR9
activation in HEK-TLR9 cells, lipo-A151 still resulted in partial inhibition when it was
incubated with cells for 3 hours prior to CpG stimulation, showing a significantly better
suppression than unmodified A151. Our results suggest that in vitro, lipid modification on
A151 not only keeps intact its suppressive properties toward TLR9 stimulation but also
leads to prolonged suppression when CpG ODN was added later.
In vivo, diacyl lipid-modified A151 accumulated in the draining LNs following
subcutaneous injection. The LNs enrichment was consistent with our previous
observations where lipid-modified ODNs bound endogenous albumin and transported to
the LNs.2 In contrast, unmodified ODN quickly diffused into blood circulation due to its
small molecular size, and exhibited minimal LNs accumulation.2,70 Flow cytometry
analysis of cells in the LNs revealed that CD11c+ dendritic cells and F4/80+ macrophages
were the major cells responsible for the uptake of lipo-A151. These cells are key APCs in
the LNs that actively bind and internalize macromolecules such as albumin.71
Using the well-studied ovalbumin as a model antigen, we also assessed the ability
of LNs targeting lipo-A151 to suppress the OVA-specific immunity in vivo.
Subcutaneously injected OVA combined with TLR9 ligand CpG ODN induced potent
CD8+ T cell and humoral responses, mimicking the inflammatory responses of
autoimmune diseases. Injection of LN-targeting lipo-A151, but not unmodified A151,
effectively suppressed OVA-specific CD8+ T cell and B cell immune responses,
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demonstrating our LNs targeting strategy was superior in the immune inhibition. In a real
situation, autoimmune diseases can be triggered by multiple TLR stimulations. 47 In our
experiments, the immune suppression by lipo-A151 appeared to be TLR9 specific, as no
suppressive effect was observed for lipo-A151 when Raw-Blue cells were stimulated with
TLR7 (imiquimod) or TLR4 (lipopolysaccharide, LPS) agonists. However, broad-spectrum
ODN-based antagonists have been recently demonstrated. For example, IMO-3100
and IMO-8400
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were reported to act as antagonists against multiple TLRs, including

TLR7, TLR8, and TLR9. Thus, it is possible to extend our approach to other endosomal
TLR antagonists with broad immunosuppressive capacity. Although clinical safety data of
phosphorothioate ODN were well documented, long-term toxicity effects are lacking. For
example, a recent study has shown the development of antibodies against
phosphorothioate ODN in patients.74 As our approach targets lipo-A151 to the LNs, it is
possible that there may exist a potent anti-lipo-A151 antibody response.
We leveraged albumin to target LNs, which accommodates a wide variety of
immune cells including APCs, T cells and B cells. Unlike nanoparticles that require
sophisticated encapsulation design or modification, this delivery system exhibits a natural,
simple and efficient way to target LNs and modulate the immune response. Our results
may pave the way to amplify the induction of immunosuppression in the immune
modulation that would target autoimmune conditions.
3.4 Conclusions
In summary, the data presented in this study suggest that the targeted delivery of
immunosuppressive ODN to LNs by “albumin-hitchhiking” improves its inhibitory activities
in vitro and in vivo. This finding emphasizes the potential of targeting immunomodulators
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to the LNs in the treatment of autoimmune diseases. Further work is required to assess
the effectiveness of suppressing human TLR-driven inflammation by lipid-modified ODN.
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CHAPTER 4 STRUCTURE-DEPENDENT STABILITY OF LIPID-BASED POLYMER
AMPHIPHILES INSERTED ON ERYTHROCYTES
4.1 Introduction
Cell-based therapy has attracted much research attention and is a rapidly
expanding field in treating many diseases, including cancer, neurological diseases, and
autoimmune disorders.75-77 As the molecular landscape of the plasma membranes
dominates interactions of cells with the surrounding environment, therapeutic cells are
often engineered to regulate cell functions such as cell survival, adhesion, migration,
targeting, cell-cell interactions, or to enable targeted drug transport.78-83 Cell surface
engineering utilizes engineering, chemistry, and biology techniques to enable
modification of cell surface molecules with targeting ligands, biological functionalities,
nanoparticles, or synthetic drugs. However, the complex and dynamic nature of cell
surface sets a significant barrier for efficient modification without physically compromising
fundamental cell functions such as viability, adhesion, migration, and immune recognition.
To date, many approaches to engineering cell surface have been developed. For
example, genetic engineering is a versatile and robust methodology to express or
suppress specific cell surface molecules.84 However, technical difficulties and safety
concerns such as limitation of cell types and restriction of introducible therapeutic
materials have confined its wide applications in the clinical setting. In parallel, another
approach that involves covalent chemical modification of cells can be utilized to conjugate
a broad range of functional molecules to the cell surface. This approach mainly engineers
functional groups including amines, thiols, and carboxyls present in proteins,
carbohydrates, or lipids on the cell surface.85 A major disadvantage of covalent
functionalization is a possible abrogation of biological functions of native proteins. Cell
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surface functionalization by lipid-based amphiphiles which are capable of spontaneously
and exogenously inserting into the plasma membranes is a great alternative approach
which can circumvent those limitations. To facilitate spontaneous membrane insertion,
these amphiphiles are designed with a functional moiety of interest, which is conjugated
to a suitable hydrophobic anchor (e.g., lipid or steroid) via a solubility-enhancing
polymeric spacer (e.g., PEG). This approach is simple, allowing rapid and uniform surface
functionalization of a wide variety of molecules without compromising the cell viability and
functions. We chose to utilize erythrocytes as mature RBCs feature long circulation time
(up to 120 days) and reduced endocytosis. Although these lipid-based amphiphiles
appear to be stably anchored on the cell surface under cell culture conditions, their
stability under mechanical stress (e.g., in the blood flow) in the presence of blood remains
uncharacterized. Since many cells used in cell-based therapies need to enter the blood
circulation, it is important to evaluate the retention of membrane-anchored amphiphiles in
vivo. In this study, we analyzed and compared the effect of the molecular structure of
lipid-based amphiphiles on their kinetic stability on the erythrocyte surface under static
condition and mechanical stress. Our results revealed that longer diacyl lipid chain offered
amphiphiles more stable retention kinetics on RBCs, while shorter PEG spacers were
preferred for greatly extended circulation half-life on RBCs in vivo. Besides, we revealed
that fluid shear stress and plasma serum promoted the release of amphiphiles anchored
on RBCs. More importantly, cationic lipids conjugated amphiphile exhibited dramatically
improved the retention kinetics on RBCs in vivo and led to a 40-fold increase in circulation
half-life compared to the anionic lipid-modified one. These results emphasized the
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significance of structural design in the retention kinetics of membrane-anchored
amphiphiles.
4.2 Materials and methods
4.2.1 Materials
DMT hexaethyloxy glycol phosphoramidite and all reagents used on ABS 394 DNA
synthesizer were purchased from Glen research or Chemgenes and used following
manufacturer’s instructions. Vybrant DiD Cell-Labeling Solution was purchased from
Thermo Scientific. 3’-FAM resin was purchased from Allele Biotechnology. DSPE-PEGNH2 was bought from Laysan Bio Inc. NHS-FITC and NHS-PEG-FITC 2000 were
purchased from Nanocs Inc. All other reagents were purchased from Sigma-Aldrich
except where otherwise noted.
4.2.2 Synthesis of diacyl lipid phosphoramidite
The C18 diacyl lipid phosphoramidite was synthesized as previously described.2 A
solution of stearoyl chloride (6.789 g, 22.41 mmol) in 1,2-dichloroethane (50 mL) was
added dropwise to a solution of 1,3-diamino-2-dydroxypropane (1.0 g, 11.10 mmol) in the
presence of 1,2-dichloroethane (100 mL) and triethylamine (2.896 g, 22.41 mmol). The
reaction mixture was stirred for 2 h at 25 °C and then heated at 70 °C overnight. The
reaction mixture was then cooled to 25 °C, filtered, and the solid was sequentially washed
with CH2Cl2, CH3OH, 5% NaHCO3, and diethyl ether. The product was dried under
vacuum to give the intermediate product as a white solid (yield: 90%). 1H NMR (300 MHz,
CDCl3, ppm): δ 6.3 (m, 2H), 3.8 (m, 1H), 3.4−3.2 (m, 4H), 2.2 (t, 4H), 1.6 (m, 4H), 1.3−1.2
(m, 60H), 0.9 (t, 6H). The intermediate product (5.8 g, 9.31 mmol) and N, Ndiisopropylethylamine (DIPEA, 4.2 mL, 18.62 mmol) was then suspended in anhydrous
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CH2Cl2 (100 mL). The mixture was cooled on an ice bath and 2-cyanoethyl N, Ndiisopropylchlorophosphoramidite (8.6 mL, 0.47 mmol) was added dropwise under dry
nitrogen. After stirring at 25 °C for 1 h, the solution was heated to 60 °C for 90 min. The
solution was washed with 5% NaHCO3 and brine, dried over Na2SO4, and concentrated
under vacuum. The final product was isolated by precipitation from cold acetone to afford
4 g (55% yield) lipid phosphoramidite as a white solid. 1H NMR (300 MHz, CDCl3): δ 6.4
(m, 2H), 3.9 (m, 2H), 3.8 (m, 2H), 3.6 (m, 2H), 3.0−2.9 (m, 2H), 2.6 (t, 2H), 2.2 (m, 4H),
1.6 (m, 6H), 1.3− 1.2 (m, 72H), 0.9 (t, 6H). 31P NMR (CDCl3): 154 ppm. The C12 diacyl
lipid phosphoramidite was synthesized following the same procedures above except that
the final product was purified by silica gel column chromatography.
4.2.3 Synthesis and purification of fluorescein-labeled lipo-(EG)n
All anionic lipo-(EG)n were synthesized using an ABI 394 synthesizer on a 1.0
micromole scale. DMT-hexaethyloxy glycol phosphoramidites were conjugated as a ‘base’
initiated

from

3’-(6-Fluorescein)

labeled

controlled

pore

glass.

All

lipophilic

phosphoramidites were conjugated as a final ‘base’ on the 5’ end of the sequence in the
DNA synthesizer. After synthesis, lipo-(EG)n were cleaved from the solid support and
deprotected, purified by HPLC using a reverse phase C4 column (BioBasic-4, 200mm X
4.6mm, Thermo Scientific), 100mM triethylamine-acetic acid buffer (TEAA, pH7.5)Methanol (0-15min, 50-100%) as an eluent. Fluorescein-labeled lipo-(EG)n typically
eluted at 14 min detected by the wavelength of 480nm. All other lipo-PEG amphiphiles
were purified by HPLC using the same eluting method.
4.2.4 Synthesis of cationic lipid
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To a 50 mL round-bottom flask, 0.6 g (3.744 mmol) of NBoc-ethylenediamine and
3.744 g (11.232 mmol) of octadecyl bromide was taken in ethyl acetate (12 mL) and
refluxed in the presence of anhydrous potassium carbonate (2.069 g; 14.976 mmol) for
24h. After completion, the mixture was diluted to 100 mL ethyl acetate, and washed with
water (2 X 100 mL), dried over anhydrous magnesium sulfate and filtered. Ethyl acetate
was removed by rotary evaporation. The residue was purified by silica gel column
chromatography to afford 0.5 g intermediate product (10% ethyl acetate in hexane, v/v,
as the eluent).MS(LC-MS) calculated: m/z 664.68; found: 665.67. To a 25 mL roundbottom flask, the intermediate product and 0.3 g methyl iodide was taken in 10mL acetone
and refluxed for 24 h. The reaction mixture was concentrated under reduced pressure
and the residue was washed twice with 50 mL hexane by centrifuge for 10 min at
maximum speed to yield 0.3 g white powder. MS(LC-MS) calculated: m/z 679.71; found:
679.55.

Scheme of synthesis of cationic lipid
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The white powder obtained (0.3 g, 0.44 mmol) was dissolved in 6 mL of anhydrous
dichloromethane (DCM) and 2 mL trifluoroacetic acid (TFA) was added. The reaction
mixture was stirred at room temperature for 24 h. After completion, the reaction mixture
was mostly concentrated by rotary evaporator and vacuumed by oil pump overnight
without further purification. Afterward, 10 mL NaOH (1N) and 10 mL dichloromethane
were added the unpurified product and the biphasic mixture was stirred at room
temperature (RT) for 2 h. The organic layer was washed with water (20 mL x 3), dried
over magnesium sulfate and filtered. The solvent in the filtrate was completely removed
by rotary evaporator and then vacuumed oil pump overnight to afford 0.15 g final product.
MS(LC-MS) calculated: m/z 579.66; found: 579.56.
4.2.5 Synthesis and purification of fluorescein-labeled cationic lipo PEG.
6 mg (10.51 μmol) of cationic lipid and 13 mg (4.2 μmol) of NHS-PEG-FITC 2000
was dissolved in 1mL dimethylformamide (DMF) and the reaction mixture was stirred at
RT overnight in the presence of 1μL of triethylamine (TEA). After completion, the mixture
was purified by HPLC as previously described.
4.2.6 Synthesis of fluorescein-labeled DSPE-PEG-2000
5.2 mg of DSPE-PEG-NH2 2000 and 1.7 mg of NHS-FITC was dissolved in 1mL
dimethylformamide (DMF) and the reaction mixture was stirred at RT overnight in the
presence of 1 μL of triethylamine (TEA). After completion, the mixture was purified by
HPLC.
4.2.7 Insertion of amphiphilic cargos on RBC ex vivo
Fresh blood was collected from Balb/c mice.10 μL whole blood was washed twice
with PBS(1x) and resuspended in 100 μL PBS. Then fluorescein labeled lipo PEG was
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added into RBC suspension at a final concentration of 5 μM and incubated at 37 °C for 1
h. Afterward, samples were washed with PBS (1 X) twice to remove excessive unbound
lipo PEG, and the residue was further incubated with whole blood, plasma serum (original
concentration in whole blood) or pure RBC suspension (original cell density in whole
blood). At designated time points, a small aliquot of the mixture was washed and then
assayed by flow cytometry.
4.2.8 In vivo kinetics study
RBC from 100 μL whole blood was treated with fluorescein-labeled lipo PEG as
described previously and resuspended in 150 μL PBS (1 X). If necessary, RBC was
further treated with DiD dye after amphiphilic cargo insertion. A Balb/c mouse was i.v.
injected with 150μL treated RBC suspension at the tail and was bled at the tail tip for
flow cytometry analysis at the designated time point.
4.2.9 Exertion of shear stress on RBCs
RBC was treated as previously described. 5 µL treated RBC was mixed with 100
µL whole blood or RBC suspension or plasm serum (diluted to physiological concentration
with 1 X PBS). After mixing, samples were then loaded onto ARES rheometer plate and
sheared at 3000 1/s for 15 min at room temperature. When shearing was completed, 1
µL fresh sample was collected immediately for flow cytometry analysis. Besides shear
stress exerted by rheometer, a syringe pump with a flow rate of 0.30 mL/min was set to
shear samples mixed with whole blood for 12 min.
4.2.10 Hemolysis of RBC
The freshly collected blood was washed with PBS (1X) and then was resuspended
in PBS (1X) with 50 times dilution. Each well 200 µL of RBCs suspension was incubated
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at 37 °C for 1 h with 5 µM amphiphilic cargoes, 1% Triton-X 100 (v/v) or without treatment
in a round-bottomed 96-well plate. For each group, samples were loaded in quadruplicate.
After incubation, the plate was centrifuged for 5 min at 500 x g to pellet intact RBCs. 100
µL of supernatant from each well was transferred into a flat-bottomed 96-well plate. The
absorbance of hemoglobin was measured by UV-vis plate reader at 540 nm. After
background subtraction, the hemolysis percentage of each group was normalized to
positive control Triton-X 100 group which represented 100% hemolysis.
4.3 Results and discussion
4.3.1 The effect of the length of lipid and PEG spacer on membrane retention time
To mimic the complex biological environment after injection, RBCs (isolated from
10 µL mouse whole blood) were incubated with 5 µM of different dye-labeled amphiphiles
(Figure 4-1 (a)) in PBS buffer, washed, and mixed with 100 µL whole blood at 37 °C for
1 h. To reduce the competitive binding from serum proteins, RBCs were separated from
serum and resuspended in PBS buffer (1 X). The retention of amphiphiles on the RBC
surface was quantified by flow cytometry over time. Like previous studies,2 amphiphilic
polymers with short lipid tail (12 carbons) rapidly dissociated from RBC surface when
mixed with whole blood. 15 minutes after incubation, no populations with fluorescent
signal was detectable in both C12-EG6 and C12-EG48 treated RBCs, suggesting a rapid
and complete release of short lipid tail (C12-PEG) from RBC surface when mixed with
blood (Figure 4-1 (b-c)). By contrast, the frequency of FITC-positive cells remained
constant in RBCs loaded with long lipid (C18)-conjugated amphiphiles for more than 3
hours (Figure 4-1 (b-c)). These results suggested that sufficient hydrophobicity was
required to firmly anchor the payload on the RBC surface in the presence of blood.
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Interestingly, we also observed the amphiphiles with a long PEG block were released at
a faster rate than those with a shorter PEG spacer, as shown in Figure 4-1 (d).
Additionally, we noticed that RBCs, but not plasma serum, played a vital role in burst
release of amphiphiles at the instance when amphiphiles-loaded RBCs were mixed with
whole blood (Figure 4-1 (e-f)). It is worth pointing out that neither PEGs modified with
C18 lipids caused hemolysis to RBCs (Figure 4-1 (g)). The reductions in fluorescence
intensity were caused by the release of amphiphiles from cells into the culture medium.
This could be due to the increased interaction between high molecular weight PEG with
serum protein.

Figure 4-1. (a) Structures of C12 and C18 lipid-modified PEG amphiphiles. (b)
Representative flow cytometry plots of FAM-labeled lipo PEG-loaded RBCs. (c) The
frequency of RBC inserted by C12 or C18 lipid conjugated (EG)6 or (EG)48 over 200 min.
(d) The relative release percentage of C18 lipid conjugated (EG)6 or (EG)48 over 200 min.
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(e) The relative burst release percentage of C18 lipid conjugated (EG) 6 or (EG)48 at
different time points over 30 min. The release of FAM lipo-(EG)n on RBC before mixing
with untreated RBC suspension was set to 0%. (f) Mean Fluorescence Intensity of FAMlabeled lipo-(EG)n on RBC before and after mixing with plasm serum diluent (1X). (g) The
viability of RBCs treated with lipo PEG amphiphiles. Each specimen was assayed with
three replicates. Error bars represent the SEM.
4.3.2 The effect of shear stress on the stability of membrane-anchored
amphiphiles
Having demonstrated the structure-based stability of amphiphiles under static
conditions, we set out to evaluate the mechanical impact to the amphiphiles loaded on
the RBCs surface. Unlike static cell culture conditions, cells are exposed to various levels
of mechanical stresses in the circulatory system under physiological conditions. Thus, the
stability of membrane-anchored amphiphiles under mechanical stress is expected to be
different when compared to that under static conditions.

Figure 4-2. (a) Representative flow cytometry plots of C18 lipo (EG)6- and lipo
(EG)48-inserted RBCs treated with or without plate shearing stress. The percentage of
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relative fluorescence decrease in C18 lipo (EG)6- and lipo (EG)48-inserted RBC after
plating shearing (b), or after syringe pumping (c). Each specimen was assayed with three
replicates. Error bars represent the SEM. Data show the mean values ± SEM. *, p < 0.05;
**, p < 0.01; ***, p < 0.001; ****, p < 0.0001; ns, not significant by using unpaired Student’s
t-tests.
To test this hypothesis, lipid-conjugated PEGs loaded RBCs were subjected to in
vitro shear conditions. A stress-controlled commercial rheometer was used to administer
shear stress to amphiphiles-loaded RBCs. As shown in Figure 4-2 (a-b), under
mechanical stress, the amphiphiles were released significantly faster than under static
conditions. After being sheared at a rate of 3000 1/s for 15 min, 7.5% C18-(EG)6 and 29.2%
C18-(EG)48 were released from RBC surfaces, as compared to 4.3% and 6.9% under
static conditions. In both dynamic and static situations, long PEG-linked amphiphile was
released at a higher rate than short PEG conjugated one, suggesting the length of PEG
spacer was an important factor that controlled the membrane stability after insertion. In
our experiment, amphiphiles loaded RBCs were mixed with freshly isolated whole blood.
It was possible that the release was caused by competitive association from unlabeled
RBCs or the serum proteins. To investigate the role of different blood components in the
observed release, amphiphiles-loaded RBCs were sheared after mixing with separated
erythrocytes or serum respectively. As shown in Figure 4-2 (b), it appeared that serum
was the dominant factor responsible for the amphiphile release. To simulate the
physiological conditions of blood flow-induced shear stress, amphiphiles-loaded RBCs
were mixed with whole blood and pumped through a capillary tube (0.1 mm in diameter).
The pressure and flow rate were controlled by regulating the pump speed to 0.30 mL/min
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for 12 min. Similar release profiles were obtained by this extracorporeal model (Figure 42 (c)). These two in vitro models demonstrated the mechanical stress accelerated the
release of lipid-based amphiphiles on RBC surface.
4.3.3 In vivo stability of membrane-anchored amphiphiles

Figure 4-3. (a) Representative flow cytometry plots of in vivo kinetics of FAMtagged lipo-(EG)6, lipo (EG)48 and DSPE-PEG 2000 loaded RBC, (b) The relative
frequency decrease of RBCs loaded with FAM-tagged C18 lipo (EG)6, lipo (EG)48 and
DSPE-PEG 2000 at different time points over 24h, (c) The relative release percentage of
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C18 lipo (EG)6, lipo (EG)48 and DSPE-PEG 2000 at different time points over 24h. Each
specimen was assayed with three replicates. Error bars represent the SEM.
To investigate in vivo stability of amphiphiles loaded on RBCs, RBCs loaded with
C18 lipid-conjugated amphiphiles were injected intravenously into mice. Blood samples
were analyzed at different time points. As shown in Figure 4-3, the release rate of
amphiphiles constructed with long PEG (C18-(EG)48) was significantly faster when
compared to that at static cultures. Under static conditions, the frequencies of RBCs
treated with C18 lipid-modified amphiphiles remained constant over 3 hours’ incubation.
However, 1 hour after injection, the fluorescence positive RBCs, carrying amphiphiles
linked with long PEG, dropped to an undetectable level. Surprisingly, the release rate of
amphiphiles conjugated with short PEG in vivo was comparable to that under static cell
culture conditions, suggesting that in vivo conditions affected longer PEG more
profoundly than short PEG in terms of the stability.
4.3.4 Cationic lipid conjugation on amphiphiles prolongs membrane retention in
vivo.
The fast dissociation rate of long PEG-conjugated amphiphiles from the RBCs
surface in vivo raises the question of how to improve it. Fluorescent lipophilic dyes (e.g.,
long-chain dicarbocyanine) are widely used to label the plasma membrane. For long-term
dye retention on cells, these dyes share some common design characteristics such as
fluorophore directly conjugated to long aliphatic tail to ensure strong hydrophobic
interactions with surrounding lipids. However, due to the relatively short hydrophilic
fluorescent head, in salt-containing buffers, these dyes rapidly form micelles or aggregate
and require special diluent for optimal staining.
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Figure 4-4. (a) Structure of fluorescein-tagged cationic DSPE-PEG-2000, (b) The
fluorescence release profiles of C18 lipo (EG)6, lipo (EG)48 and cationic DSPE-PEG-2000
under static conditions, (c) Representative flow cytometry plots of in vivo kinetics of
cationic amphiphile-loaded RBCs, (d) The relative frequency decrease of RBCs loaded
with cationic amphiphiles at different time points over 72 h, (e) The relative release
percentage of cationic amphiphiles at different time points over 72 h. Each specimen was
assayed with three replicates. Error bars represent the SEM. Data show the mean values
± SEM. *, p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001; ns, not significant by oneway ANOVA with Bonferroni post-test.
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In many cases, a long PEG linker is preferred for the retention of cellular
functions.86,87 However, the fast dissociation rate of C18 lipo (EG)48 from RBCs surface
in vivo suggests that hydrophobic interaction alone is insufficient for the retention of
payload with the long PEG linker. Since the plasma membranes are negatively charged,
we postulate that a positively-charged lipid tail would offer electrostatic attraction besides
hydrophobic interaction and thus prolong the retention time of long PEG conjugated
amphiphiles on the plasma membranes. We synthesized a cationic C18 lipid and
conjugated it with fluorescein-labeled long PEG spacer (PEG 2000 averagely equals to
45 EG units) (Figure 4-4 (a)). The retention kinetics of cationic C18 lipo (EG)45 was
dramatically improved under ex vivo static conditions (Figure 4-4 (b)). More importantly,
cationic lipid significantly prolonged circulation half-life of amphiphiles conjugated with
long PEG spacer in vivo as compared to the original phospholipid-modified analogs,
characterized by a 40-fold improvement in retention half-life on RBCs. (Figure 4-4 (c-e)).
24 hours after injection, only 24.3 % of cationic amphiphile was released from RBCs, as
compared to 72.2% of anionic counterpart. There were a considerable amount of cargos
remaining inserted on RBCs even after 48 hours of circulation. We concluded that a
cationic lipid design facilitated the long-term retention of amphiphiles anchored on RBCs
during circulation.
4.4 Conclusions
In summary, we studied the structural factors that affected the retention kinetics of
lipid-based amphiphiles anchored on RBCs. The results revealed that longer diacyl lipid
contributed to more stable retention kinetics of amphiphiles, while shorter PEG spacers
had more profound impact on the stability of amphiphiles anchored on RBCs in vitro and
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in vivo. In addition, we identified that fluid shear stress accelerated the release of
membrane-anchored amphiphiles from RBCs and serum albumin was a dominant factor
that controlled the retention kinetics of amphiphiles loaded on RBCs as well. Furthermore,
in contrast to an anionic lipid modification, a cationic lipid conjugation to long PEG block
led to a 40-fold extension in circulation half-life on RBCs in vivo, indicating that a cationic
structure design of amphiphile was preferred for long-term retention on RBCs. This study
underscored the rational structural design in the retention kinetics of membrane-anchored
amphiphiles during systemic circulation, and these findings might be of great interest and
significance for the advancement of cell-based drug delivery.
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CHAPTER 5 LACE MOLECULAR VACCINE WITH TLR7/8 ADJUVANT BOOSTER
TO ENHANCE IMMUNOGENICITY
5.1 Introduction
Systemic lupus erythematosus (SLE) is an autoimmune disease where the host
immune system wrongly mounts immune attacks against a large part of healthy tissues.
In SLE patients, elevated serum levels of interferon-α (IFN-α) are closely related to
disease activity and severity.50 The increased levels of IFN-α can be induced by DNA and
RNA viruses and immune complexes (ICs) that consist of autoantibodies specific to
endogenous DNA- and RNA-derived self-antigens.50 In innate immunity, TLR7 and TLR9
signaling can respectively sense mammalian RNA and DNA in the forms of ICs via
pathogen-associated molecular patterns (PAMPs) and thus induce IFN-α production in
plasmacytoid dendritic cells (pDC).13,88 Accordingly, inhibitors specific to TLR7 and TLR9
can be utilized to suppress IFN-α production and thus treat SLE patients. To date, a series
of oligonucleotide-based inhibitors of TLR signaling have been developed.50,55 To
leverage the “albumin-hitchhiking” delivery approach, we evaluated the therapeutic
efficacy of lipid-modified ODN A151 which showed improved immunosuppressive activity
in inhibiting TLR9-mediated immune activation when compared to the unmodified
counterpart.
To further expand the pool of lipo suppressive ODNs, we set out to investigate the
therapeutic benefits of lipid-modified TLR7 inhibitor. TLR7 is an endosomal receptor
which binds viral single-stranded RNA such as RNA of hepatitis B virus, or synthetic
guanine-rich RNA base analogs such as R848 and imiquimod (IMQ).89,90 As one of the
lead compounds of TLR7 agonists, IMQ has been approved by FDA for topical application,
which is effective in treating several major skin tumors and cutaneous metastases.91,92
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To evaluate the efficacy of lipid-modified immunoregulatory sequence 954 (lipo IRS 954),
a dual inhibitor of TLR7 and TLR9 signaling,50 we used IMQ as a primary ligand to induce
TLR7-mediated immune activation.
Surprisingly, we found that lipo IRS 954 enhanced TLR7-mediated activation
instead of showing TLR7-specific immunosuppression. The immune enhancement was
also observed in another potent TLR7-specific antagonist, 20-mer thymidine
oligodeoxynucleotide (T20),90 showing that lipid-modified T20 (lipo T20) also significantly
improved immune activation of IMQ. Interestingly, in the absence of serum albumin, lipo
T20 markedly inhibited IMQ-induced activation in Raw-Blue cells, suggesting an
indispensable role of albumin in the reversal of biological properties of lipo T20. Moreover,
bovine serum albumin (BSA)-T20 conjugate, which was obtained via covalently
conjugating T20 to BSA, exhibited potent immunosuppression in TLR7-mediated immune
activation. Therefore, lipid modification converted the oligonucleotide-based TLR7
inhibitors into TLR7 adjuvant boosters in the presence of albumin. Because of its small
molecular size, unformulated IMQ injected subcutaneously showed little LN accumulation.
Instead, IMQ tends to diffuse into the bloodstream and activate the immune system
nonspecifically. We reasoned that lipo T20, with intrinsic LN-targeting capability via
“albumin-hitchhiking”, might be able to enhance the adjuvant activities of IMQ, allowing
dose-sparing and reducing toxicity. As expected, subcutaneous administration of
“IMQ/protein antigen” vaccine laced with lipo T20 in mice resulted in a five-fold increase
in T-cell priming and enhanced antibody response in comparison to the parent vaccine.
Accordingly, lacing vaccine formula with the adjuvant booster is a novel and simple
approach to enhance the immunogenicity of molecular vaccines.
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5.2 Materials and methods
5.2.1 Materials
All reagents and commercially available compounds for DNA synthesis were
purchased from Glen research (Sterling, VA) or Chemgenes (Wilmington, MA) and used
following the manufacturer’s instructions. 3’- Fluorescein amidite (FAM) labeled controlled
pore glass was purchased from Allele Biotechnology (San Diego, CA). Fatty acid-free
BSA was purchased from Sigma-Aldrich. Ovalbumin protein was purchased from
Worthington Biochemical Corporation (Lakewood, NJ). Murine MHC class I tetramer was
obtained from MBL international Corporation (Woburn, MA). Antibodies were purchased
from eBioscience (San Diego, CA) or BD Bioscience (San Jose, CA). Imiquimod,
resiquimod, gardiquimod were purchased from Cayman Chemical Company (Ann Arbor,
MI). 1-(4-(Aminomethyl)benzyl)-2-butyl-1Himidazo[4,5-c]quinolin-4amine dihydrochloride
was bought from Synnovator, Inc (Durham, NC). CL075, TLR8-506, poly I:C and all cell
lines were purchased from InvivoGen (San Diego, CA). Cy5-labeled T20 was purchased
from IDT (Coralville, Iowa). All other reagents were from Sigma-Aldrich and used as
received except where otherwise noted.
5.2.2 Synthesis of diacyl lipid phosphoramidite
The diacyl lipid phosphoramidite was synthesized as previously described.2 A
solution of stearoyl chloride (6.789 g, 22.41 mmol) in 1,2-dichloroethane (50 mL) was
added dropwise to a solution of 1,3-diamino-2-dydroxypropane (1.0 g, 11.10 mmol) in the
presence of 1,2-dichloroethane (100 mL) and triethylamine (2.896 g, 22.41 mmol). The
reaction mixture was stirred for 2 hours at 25 °C and then heated at 70 °C overnight. The
reaction mixture was then cooled to 25 °C, filtered, and the solid was sequentially washed
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with CH2Cl2, CH3OH, 5% NaHCO3 and diethyl ether. The product was dried under
vacuum to give the intermediate product as a white solid (yield: 90%). 1H NMR (300 MHz,
CDCl3, ppm): δ 6.3 (m, 2H), 3.8 (m, 1H), 3.4-3.2 (m, 4H), 2.2 (t, 4H), 1.6 (m, 4H), 1.3-1.2
(m, 60H), 0.9 (t, 6H). The intermediate product (5.8g, 9.31mmol) and N, NDiisopropylethylamine (DIPEA, 4.2mL, 18.62mmol) was then suspended in anhydrous
CH2Cl2 (100 mL). The mixture was cooled on an ice bath and 2-Cyanoethyl N, Ndiisopropylchlorophosphoramidite (8.6 mL, 0.47 mmol) was added dropwise under dry
nitrogen. After stirring at 25 °C for 1 hour, the solution was heated to 60 °C for 90 min.
The solution was washed with 5% NaHCO3 and brine, dried over Na2SO4 and
concentrated under vacuum. The final product was isolated by precipitation from cold
acetone to afford 4 g (55% yield) lipid phosphoramidite as a white solid. 1H NMR (300
MHz, CDCl3): δ 6.4 (m, 2H), 3.9 (m, 2H), 3.8 (m, 2H), 3.6 (m, 2H), 3.0-2.9 (m, 2H), 2.6 (t,
2H), 2.2 (m, 4H), 1.6 (m, 6H), 1.3-1.2 (m, 72H), 0.9 (t, 6H). 31P NMR (CDCl3): 154 ppm.
5.2.3 Synthesis and purification of oligonucleotides
All ODN sequences were synthesized using an ABI 394 DNA synthesizer on a 1.0
micromole scale. All lipophilic phosphoramidites were conjugated as a final ‘base’ on the
5’ end of oligos. Lipophilic phosphoramidite was dissolved in dichloromethane and
coupled to oligos in DNA synthesizer (15 min coupling time). After the synthesis, DNA
was cleaved from the solid support, deprotected, and purified by reverse phase HPLC
using a C4 column (BioBasic-4, 200mm x 4.6mm, Thermo Scientific), 100mM
triethylamine-acetic acid buffer (TEAA, pH 7.5)-methanol (0-5 min, 50-80%; 5-15 min, 80100%) as an eluent. Lipophilic ODNs typically eluted at 13 min while unconjugated oligos
eluted at 7 min. Fluorescein-labeled ODNs were synthesized using 3’-(6-Fluorescein)

72
tagged controlled pore glass. Lipid-conjugated IRS 954 (5’-tgctcctggaggggttgt-3),50 T20
(5’-tttttttttttttttttttt-3’),90,93,94 ODN 2087 (5’- tcctgagcttgaagt-3’)95 CpG ODN 1826 (5’tccatgacgttcctgacgtt-3’)26 (phosphorothioate linkage) were synthesized using the above
method.
5.2.4 In vitro TLR reporter cells stimulation
HEK-Blue™-mTLR7, mTLR8, hTLR7, hTLR8, and RAW-BlueTM cells were
purchased from InvivoGen and were used to evaluate bioactivities of lipo ODNs and TLR
7/8 ligands in vitro. All these cell lines were cultured with DMEM supplemented with 10%
FBS, 1% P/S and 100 μg/mL Normocin at 37 °C with 5% CO2. In a typical procedure, 2
μM IMQ and 1 μM unmodified T20 or lipo T20 (or lipo IRS 954 or lipo ODN 2087) were
added to InvivoGen HEK-Blue™ murine or human TLR7/8 or RAW-Blue™ mouse
macrophage reporter cells, both of which are engineered with secreted embryonic
alkaline phosphatase (SEAP) reporter gene. After incubating for 24 h, SEAP levels were
quantified by developing supernatants with QuantiBlue™ substrate for 1 h and reading
absorption at 620 nm, following manufacturer’s instructions.
5.2.5 In vitro cellular uptake and confocal imaging
DC 2.4 cells were cultured with RPMI-1640 supplemented with 10% FBS and 1%
P/S; Raw-Blue cells were cultured as previously described. 1 µM FAM-labeled unmodified
T20 or lipo T20 at 37 °C for 12 h. After incubation, cells were washed twice with 1 x PBS
by centrifuge at 800X g for 5 min prior to flow cytometry quantification. To visualize in vitro
cellular uptake, DC 2.4 cells or Raw-Blue cells were cultured and incubated under the
same experimental conditions and were subjected to confocal imaging by Zeiss LSM 510
microscope. To investigate endocytosis pathways, DC 2.4 cells seeded in 12-well plates
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(5 X 105 cells/well) were pretreated with endocytic inhibitors at 37 °C for 30 min in OptiMEM and then treated with 1 μM Alexa-647 BSA or 1 μM FAM-labeled T20 and Lipo T20
at 37 °C for 2 h. Inhibitors: 5 μg/mL Filipin; 50 μM EIPA; 300mM Sucrose were tested.
5.2.6 Albumin-ODN conjugates
Thiol-terminated T20 or CpG was synthesized by solid-phase coupling of
fluorescein-labeled T20 or CpG with C6 S-S CE phosphoramidite (Thiol-Modifier C6 S-S,
ChemGenes) at the 5’ end of the oligo. 27 mg Bovine serum albumin (BSA, 50 mg/μL in
PBS) was co-dissolved with 0.32 mg N-(β-Maleimidopropyloxy) succinimide ester (BMPS,
30mg/ml in DMSO, Aldrich) and the mixture was agitated at RT for 2h. Extra BMPS was
removed by diluting in PBS solution and passing the mixture through a PD MidiTrap G25 desalting column (GE Healthcare) and concentrated and further purified by centrifuge
filter tube (30K MWCO). 125 nmol of 5’-disulfide-modified fluorescein-T20 or CpG was
pre-activated by 1000 nmol TCEP (3,3’,3’’-Phosphanetriyltripropionic acid, 100mM in
deionized water) and then purified through centrifuge filter tube (30K MWCO).
Subsequently, activated T20 or CpG was added to the modified-BSA solution. The
mixture was agitated overnight at RT and unconjugated T20 or CpG was removed by
configuring filter tube (30K MWCO); free T20 or CpG removal was confirmed by sizeexclusion chromatography.
5.2.7 Preparation of murine splenocytes
Spleens were freshly collected from mice and were cut into small pieces. A plunger
end of a syringe was used to further disassemble spleen tissues into single cells. The cell
suspension was subsequently filtered and washed. Lysing buffer was utilized to remove
excessive red blood cells. After twice washes, 95% viability of splenocytes was confirmed
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by trypan blue. Splenocytes were resuspended in RPMI-1640 supplemented with 10%
FBS and 1% P/S. Splenocytes were seeded at 1 x 106 cells/ml in 200μL in a 96-well plate.
Splenocytes were treated with 2 μM IMQ alone or plus 1 μM T20 or lipo T20 for 24 h
under culturing conditions.
5.2.8 Preparation of primary human cells
Whole blood was obtained from Red Cross where healthy volunteers had provided
informed consent to donate blood. PBMC were isolated by density gradient centrifugation
using Histopaque-1077 (Sigma-Aldrich). The mononuclear cells were washed twice with
cold PBS (1X) and resuspended in completed RPMI-1640 supplemented with 10% FBS
and 1% penicillin/streptomycin. PBMC were seeded at 2 x 106/ml in 200 μL in a 96-well
plate. Plasmacytoid DC (pDC) monocytes were isolated from PBMC by immunomagnetic
bead positive selection using BDCA-4 according to manufacturer’s instructions. Briefly,
PBMC were first blocked with human FcR blocking reagent and then incubated with
immunomagnetic MACS microbeads, and the labeled cells were collected with Miltenyi
columns. The positively selected cells were resuspended in complete RPMI and seeded
at 1 x 106 cells/ml in 200μL in a 96-well plate. pDC purity and viability from positively
isolated cells and populations of cells were determined by flow cytometry.
5.2.9 Determination of secreted cytokines
Supernatants collected from splenocytes suspension or human PBMC suspension
after incubation were separately analyzed for IL-6, IL-12p40, TNF-α and IFN-α by ELISA
following manufacturer’s instructions.
5.2.10 In vivo immunization
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C57BL/6 mice (6-8 weeks) were immunized by a homologous prime-boost regimen:
animals were primed on day 0 and boosted on day 14 with 50 µg Ovalbumin and 15 µg
IMQ mixed with or without 6.2 nmol lipo T20 dissolved in PBS. The volume of all vaccine
injections was 100 µL/animal. All injections were performed subcutaneously at the base
of the tail.
5.2.11 Tetramer Staining
Seven days after the final immunization, blood samples were collected. Red blood
cells were lysed by ACK lysing buffer. Cells were then blocked with Fc-blocker (antimouse CD16/CD32 monoclonal antibody) and stained with SIINFEKL loaded
phycoerythrin-labeled tetramers (Beckman Coulter) and anti-CD8-APC (ebioscience) for
30 min at 4 oC. Cells were washed twice, resuspended in FACS buffer, and analyzed on
Attune Focus flow cytometer. Analysis typically gated on live CD8+, Tetramer positive
cells.
5.2.12. Intracellular cytokine staining
Peripheral blood was lysed with ACK buffer and washed with PBS twice. Purified
cells were seeded in 96-well round-bottomed plates and pulsed with 10 μg/mL OVA
peptide SIINFEKL for 2 h at 37 °C in T-cell media (RPMI-1640, 10% FBS, 50 μM βmecaptoethanol, 1% P/S), followed by the addition of brefeldin A for 4 hours. Cells were
stained with anti-CD8-APC and then fixed using Cytofix following the manufacturer’s
instructions. Next, cells were washed and permeabilized. Intracellular staining for antiIFN-γ-PE and anti-TNF-α-FITC was performed following the manufacturer’s instructions
and cells were analyzed by Attune Focus flow cytometer.
5.2.13 ELISA for OVA-specific IgG
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Mice were bled, and blood samples were collected. Serum anti-OVA IgG levels
were determined by ELISA: 96-well plates were coated overnight with 10 μg/ml OVA in
PBS and blocked with 1% BSA in PBS. After incubation of serum samples for 1h at a
series of dilutions, plates were washed with PBS/1% Tween-20. Goat anti-mouse IgG
conjugated to Horseradish peroxidase (HRP) was added at 1 μg/ml for 30min. Plates
were washed with PBS/1% Tween-20 and ELISA was developed by (3,3’,5,5’Tetramethylbenzidine) (TMB, ebioscience). The reaction was stopped by 1M H2SO4 and
the absorbance was read at 450 nm and 570 nm using a plate reader.
5.2.14 Statistical analysis
All plots show mean values and error bars represent the SEM. One-way analysis
of variance (ANOVA), followed by a Bonferroni post-test, was used to compare >2 groups.
*, p<0.05; **, p<0.01; ***, p<0.001; ns, not significant unless otherwise indicated.
Statistical analysis was performed using GraphPad Prism software (San Diego, CA).
5.3 Results and discussion
5.3.1 Lipid conjugation specifically reverses oligonucleotide-based TLR7
inhibitors
Our previous finding demonstrated that lipid-modified oligonucleotide-based TLR9
inhibitor was more potent and efficacious than unmodified oligo in targeting LNs and
suppressing CpG-induced immune activation. Inspired by this study, we aimed to take
advantage of lipid functionalization in other oligonucleotide-based TLR inhibitors to further
expand the pool of lipo suppressive ODNs. We set out to investigate the therapeutic
efficacy of lipid-modified IRS 945 in suppressing TLR7-mediated immune activation and
alleviating the severity of SLE. As shown in Figure 5-1 (a), we first used imiquimod (IMQ)
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to stimulate TLR7-mediated immune activation in Raw-Blue reporter cells and determined
immunosuppressive capability of unmodified or lipo IRS 954 by quantifying the level of
TLR7-induced NF-κB activation. However, the results showed that lipo IRS 954 markedly
enhanced TLR7-mediated activation, while the unmodified IRS 954 itself remained
immunosuppressive toward TLR7 signaling (Figure 5-1 (b)).

Figure 5-1. (a) Structure of imiquimod (IMQ) and single-stranded DNA sequence
of IRS 945 and lipo IRS 954, (b) Raw-Blue cells were stimulated with 2 μM IMQ alone or
IMQ + 1 μM IRS 954 or lipo IRS 954 for 24 h, (c) Raw-Blue cells were stimulated with 2
μM IMQ alone or plus 1 μM T20 or lipo T20 for 24 h, (d) Raw-Blue cells were stimulated
with 10 μg/ml Poly I:C, 2 μM IMQ and 100 nM CpG ODN 1826 alone, or plus 1 μM lipo
T20 respectively for 24 h. Data show the mean values ± SEM. *, p < 0.05; **, p < 0.01;
***, p < 0.001; ****, p < 0.0001; ns, not significant by one-way ANOVA with Bonferroni
post-test.
Based on these compelling results, we hypothesized that lipid modification might
be used to reverse the immunological properties of oligonucleotide-based TLR7 inhibitors.
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To test this hypothesis, we conjugated the C18 lipid tail to another classic oligonucleotidebased TLR7 inhibitor, 20-mer thymidine oligodeoxynucleotide, to generate lipo T20 and
then tested it following previous experimental settings. Similar to lipo IRS 954, lipo T20
enhanced the immunostimulatory activities of IMQ by 5 folds. In contrast, unmodified T20
was suppressive toward IMQ stimulation, lowering the NF- κB activation by 2 folds
(Figure 5-1 (c)). The enhancement of NF-κB activation by lipo T20 appeared to be TLR7
specific, as no enhancement was observed when Raw-Blue cells were stimulated by CpG
ODN (a TLR9 ligand) and Poly I:C (a TLR3 ligand) (Figure 5-1 (d)). Collectively, we found
that lipid conjugation could specifically reverse the inhibitory effect of oligonucleotidebased TLR7 inhibitors.
5.3.2 The role of albumin in the mechanism of action

Figure 5-2. (a) Raw-Blue cells were stimulated with 2 μM IMQ alone or plus 1 μM
lipo T20 or lipo (EG)48 for 24 h. (b) Flow cytometry analysis of DC 2.4 cells treated with
1 μM of FAM-T20 or FAM-lipo T20 for 12 h or 24 h at 37 °C. (c) Raw-Blue cells were
stimulated with 2 μM IMQ alone or plus 1 μM lipo T20 or 5 μM T20 for 24 h. (d)
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Representative confocal images of DC 2.4 cells treated with 1 μM Cy5-labeled T20 and
FAM-labeled lipo T20 simultaneously. Scale bar: 10 μm. Data show the mean values ±
SEM. *, p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001; ns, not significant by oneway ANOVA with Bonferroni post-test or unpaired Students’ t-test.
Structurally, lipo T20 might be stimulatory due to the lipid moiety. To test whether
lipid tail can stimulate cells, we conjugated the same diacyl lipid to oligo-mimicking
“hexaethyleneglycol” blocks via DNA synthesizer. The amphiphilic polymer lipo (EG)48
has a length comparable to lipo T20. Lipid tail itself did not affect IMQ-induced activation
(Figure 5-2 (a)). According to our previous studies, lipid conjugation typically resulted in
increased cellular uptake. The results here also showed that DC 2.4 cells preferentially
internalized more lipo T20 than unmodified T20 over 24 h incubation (Figure 5-2 (b)). We
then speculated that quantitatively increased cellular uptake of T20 might contribute to
the qualitative reversal of lipo T20’s immunosuppressive properties. However, high-dose
T20, five times more concentrated than lipo T20, exhibited significantly enhanced
inhibition in IMQ-elicited activation (Figure 5-2 (c)), suggesting an enhanced uptake was
not responsible for the improved stimulation. In addition, lipid modification did not alter
cellular localization of T20, as demonstrated in confocal imaging of DC 2.4 cells treated
with 1 μM Cy5-labeled T20 and FAM-labeled lipo T20 simultaneously (Figure 5-2 (d)).
A previous work reported that poly-thymidine could interact with TLR7 ligands like
IMQ.90 Therefore, we postulated that lipo T20, with uptake-facilitating lipid tail, might
promote cellular uptake of TLR7 ligands via ODN-drug intercalation and subsequently
enhanced IMQ-induced activation. To verify this possibility, we used a functionalizable
TLR7 analog of IMQ, “1-(4-(Aminomethyl) benzyl)-2-butyl-1Himidazo[4,5-c]quinolin-
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4amine” (IMDQ), for quantification of cellular uptake and fluorescence imaging. Flow
cytometry data indicated that neither T20 nor lipo T20 increased cellular uptake of FITClabeled IMDQ (Figure 5-3 (a)). Besides, confocal imaging indicated that IMDQ was
primarily in the endosomal-lysosomal compartment in the presence of T20 or lipo T20
(Figure 5-3 (b)). Taken together, the data we showed here demonstrated that lipid
conjugated T20 was a TLR7 adjuvant enhancer which dramatically improved the
immunostimulatory effect of IMQ.

Figure 5-3. (a) Structure of FITC labeled-IMDQ and flow cytometry analysis of
Raw-Blue reporter cells treated with 2 μM FITC-IMDQ alone or in combination with 1 μM
T20 or lipo T20, (b) Representative confocal images of DC 2.4 cells which were treated
with 2 μM Cy5-labeled IMDQ alone or in combination with 1 μM T20 or lipo T20 for 24 h
and then washed and stained with 50 nM LysoTracker Green and 300 nM DAPI (4’, 6diamidino-2-phenylindole) following manufacturer’s instructions. Scale bar: 10 μm. Data
show the mean values ± SEM. *, p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001;
ns, not significant by one-way ANOVA with Bonferroni post-test.
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Figure 5-4. (a) Flow cytometry analysis of DC 2.4 cells treated with endocytosis
inhibitors for 30 min, followed by 1.5 h incubation with 1 μM FAM-labeled T20 or lipo T20
or 1 μM Alexa-647 BSA respectively, (b) Raw-Blue reporter cells were stimulated with 2
μM IMQ alone or in combination with 1 μM T20 or lipo T20 under FBS-free and normal
culture conditions respectively for 24 h, (c) Flow cytometry analysis of Raw-Blue reporter
cells which were cultured with complete or FBS-free medium separately for 24 h and then
stained with Annexin V and PI for cell apoptosis assay, (d) Raw-Blue reporter cells were
stimulated with 2 μM IMQ alone or in combination with 1 μM lipo T20 pre-complexed with
BSA at 1: 1 and 1: 2 ratio respectively under FBS-free (O/F) condition for 24h; Meanwhile,
Raw-Blue reporter cells were stimulated with 2 μM IMQ alone or in combination with 1
μM lipo T20 under FBS-supplemented (W/F) condition for 24 h. Data show the mean
values ± SEM. *, p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001; ns, not significant
by one-way ANOVA with Bonferroni post-test.
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As lipo T20 contained a lipophilic domain which enabled avid “albumin-binding”, it
was reasonable to ask the question of whether albumin was playing a role in enhancing
IMQ stimulation by lipo T20. In fact, the culture medium was normally supplemented with
fetal bovine serum (FBS) containing excessive albumin relative to the quantity of lipo T20
utilized, so it was highly possible that lipo T20 would bind to serum albumin (FBS) once
added to culture medium. As part of the proof to support this hypothesis, we observed
that endocytosis pathway of lipo T20 exactly mimicked that of BSA, which was
internalized mainly via macropinocytosis (EIPA) and clathrin-mediated endocytosis
(Sugar) in DC 2.4 cells (Figure 5-4 (a)). Our observation agreed with previous studies on
endocytosis of lipid-modified ODN conjugates and albumin.96-98 To further determine the
role of albumin in the enhanced stimulation of IMQ, Raw-Blue cells were seeded overnight
and then stimulated as previously described using the serum-free medium. Interestingly,
lipo T20 completely suppressed IMQ-induced NF-κB activation under FBS-free culture
conditions, indicating that albumin played an important role in the effect of lipo T20 on
TLR 7 stimulation (Figure 5-4 (b)). Meanwhile, we ruled out the cell viability as a potential
factor for downregulated NF-κB stimulation by confirming that the survival rate of RawBlue cells was unchanged under the FBS-free culture condition (Figure 5-4 (c)).
Since lipo ODN is able to hijack albumin and subsequently accumulates in APCs
residing in LNs,2 forming stable albumin-lipo ODN complexes in physiological condition
is a prerequisite for survival on their thorny way to LNs and lymphoid APCs. Similarly, lipo
T20 should be able to complex with albumin under FBS-supplemented culture condition
before being transported into cells. Besides, our research into erythrocytes insertion
revealed that amphiphilic polymer was unable to massively insert into the plasma
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membrane in the presence of blood serum. Collectively, these reasonings pointed to a
“fact” that lipo T20 was transferred into cells in the form of lipo T20-albumin complex. To
verify our postulation, we pre-incubated lipo T20 with BSA at a ratio of 1:1 and 1:2 for 1h
and then treated pre-seeded Raw-Blue cells with 1 μM BSA-complexed lipo T20 under
FBS-free condition. The results clearly showed that lipo T20’s capability of suppressing
IMQ-induced activation was progressively abrogated as the ratio of pre-complexed BSA
increased (Figure 5-4 (d)). Hence, we confirmed that the reversal of lipo T20’s biological
capability of inhibiting TLR7 signaling primarily resulted from albumin which formed
albumin-lipo T20 complex via noncovalent interaction.

Figure 5-5. (a) Representative confocal images of Raw-Blue reporter cells treated
with 1 μM FAM-labeled T20 or FAM-labeled lipo T20 under FBS-supplemented condition,
or (b)under FBS-free condition, and then washed and stained with 50 nM LysoTracker
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Red following manufacturer’s instructions. Scale bar: 10 μm. (c) Raw-Blue cells were
stimulated with 2 μM IMQ alone or in combination with 1 μM disulfide bond-linked T20 or
lipo T20 or BSA-T20 conjugate under FBS-supplemented condition, (d) under FBS-free
condition, for 24 h. Data show the mean values ± SEM. *, p < 0.05; **, p < 0.01; ***, p <
0.001; ****, p < 0.0001; ns, not significant by one-way ANOVA with Bonferroni post-test.
Additionally, we also illustrated that both T20 and lipo T20 colocalized with
lysosomes regardless of the presence of FBS, suggesting that albumin did not
significantly affect lipo T20’s intracellular destination (Figure 5-5 (a-b)). However, a
covalently-synthesized BSA-T20 conjugate failed to reverse the intrinsic properties of T20
under both FBS-supplemented and FBS-free culture conditions as it greatly suppressed
IMQ-induced activation (Figure 5-5 (c-d)). Accordingly, the reversal of lipo T20’s
immunological property was more than due to the endocytosis pathway via hijacking
albumin and was not due to quantitatively increased cellular uptake.
5.3.3 Optimization of TLR7 adjuvant booster
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Figure 5-6. (a) Structure of C18 diacyl lipid conjugated poly-oligo(dT) and C14
diacyl lipid conjugated T20, (b) Raw-Blue reporter cells were stimulated with 2 μM IMQ
alone or with 1 μM lipo T10, lipo T20, lipo T25 and lipo T50 for 24 h, (c) Raw-Blue reporter
cells were stimulated with 2 μM IMQ alone or in combination with 1 μM C14 diacyl lipidmodified T20 or C18 diacyl lipid-modified T20 for 24 h, (d) Raw-Blue cells were stimulated
with 2 μM IMQ alone or in combination with 1 μM lipo T10, lipo T20, lipo T25 and lipo T50
for 24 h, (e) Structure of 3’-and 5’-modified Cholesterol T20, (f) HEK mTLR7 reporter cells
were stimulated with 2 μM IMQ alone or in combination with 1 μM 3’- and 5’-modified
Cholesterol T20 for 24 h, (g) HEK mTLR8 reporter cells were stimulated with 2 μM R848
alone or in combination with 1 μM 3’-and 5’- modified Cholesterol T20 for 24 h. Data
show the mean values ± SEM. *, p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001;
ns, not significant by one-way ANOVA with Bonferroni post-test.
To optimize TLR7 stimulation enhancing efficacy, we synthesized a series of lipo
poly-oligo-deoxythymidine (poly-Oligo(dT)) to treat Raw-Blue cells along with IMQ
(Figure 5-6 (a)). As shown in Figure 5-6 (b), lipo T20 or lipo T25 mixed with IMQ induced
the highest level of NF-κB stimulation. In contrast, lipo T10 showed little effect on IMQmediated activation, while lipo T50 slightly suppressed TLR7 signaling. ODNs conjugated
with short diacyl lipids, such as C12 and C14 lipid chains, were less effective in targeting
LNs due to relatively weak hydrophobic interaction between lipid tails and albumin.2
However, we observed that C14 lipid-modified T20 gave a comparable level of immune
activation when mixed with IMQ in vitro (Figure 5-6 (c)). In addition, we found that lipo
T20 was unable to enhance IMQ-induced activation once the ratio of lipo T20 to IMQ was
less 1:10, while no further potency-enhancing effect was observed when this ratio was
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greater than 5:10 (Figure 5-6 (d)). Although most lipo ODNs were modified at 5’ terminal
of ODN due to simplicity and cost of synthesis, 3’-terminal might give different levels of
effects, as reported on the modification of CpG oligonucleotides. To test whether lipid
modification at 3’ terminal of T20 would affect immune modulation, we synthesized 5’and 3’-conjugated lipo T20 by using a 5’-cholesterol phosphoramidite and a 3’-cholesterol
beads respectively (Figure 5-6 (e)). Since T20 itself was a TLR8 booster as well as a
TLR7 inhibitor, we used murine TLR7 and TLR8 reporter cells separately for NF-κB
stimulation assay. The results revealed that both 5’- and 3’-modified T20s were able to
significantly enhance IMQ-induced stimulation in murine TLR7 cells, while both were
functionally compromised after modification and unable to activate resiquimod (R848)elicited murine TLR8 signaling (Figure 5-6 (f-g)). Together, these data demonstrated that
lipid poly-oligo(dT) with 20~25-mer was the optimal structure to induce the highest level
of TLR7-mediated NF-κB activation, and T20 modified with less hydrophobic lipid tail,
compared to C18 lipid chain, at either 5’ or 3’ terminal was able to reverse the TLR7specific suppression.
5.3.4 Immune modulation on TLR7 and TLR8 reporter cells
To investigate differential modulation of lipo T20 on TLR7 and TLR8, we evaluated
half-maximal effective concentration (EC50) and potency of several classic TLR7/8
ligands in murine TLR7 and TLR8 reporter cells. The results implied that lipo T20
significantly lowered EC50 and improved the potency of IMQ, CL075, and R848, while
T20 functioned in an opposed trend in murine TLR7 reporter cells (Figure 5-7 (a-c)). On
the contrary, T20 was able to activate murine TLR8 only if mixed with a high dose of
TLR7/8 ligands, while lipo T20 showed no effect (Figure 5-7 (d-f)). To determine the
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levels of overall stimulation, we repeated the titration experiments in Raw-Blue reporter
cells. Similar to that in murine TLR7 reporter cells, lipo T20 improved the potency and
EC50 of these ligands and T20 suppressed their NF-κB stimulation in Raw-Blue reporter
cells, indicating that although lipo T20 and T20 exhibited opposite stimulation toward
TLR7 and TLR8, lipo T20 enhanced the overall NF- κB stimulation. These data clearly
demonstrated lipo T20, but not T20, could act as an adjuvant enhancer to improve the
immune stimulation of TLR7 (Figure 5-7 (g-i)).

Figure 5-7. (a-c) HEK mTLR7 reporter cells were stimulated with IMQ, CL075,
R848 at indicated concentrations alone or in combination with 1 μM T20 or lipo T20 for
24 h, (d-f) HEK mTLR8 reporter cells were stimulated with IMQ, CL075, R848 respectively
at indicated concentrations alone or in combination with 1 μM T20 or lipo T20 for 24 h,
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(g-i) Raw-Blue reporter cells were stimulated with IMQ, CL075, R848 respectively at
indicated concentrations alone or in combination with 1 μM T20 or lipo T20 for 24 h.
Human and murine TLR7/8 shared many similarities in genetic sequence and
function. To determine whether the above results could be translated to human cells, we
stimulated human TLR7 reporter cells with several lipid-modified oligonucleotides. The
results showed that besides lipo T20 and lipo IRS 954, lipid-modified ODN 2087, originally
a human TLR7 and TLR8 inhibitor, also remarkably enhanced IMQ-induced NF-κB
stimulation (Figure 5-8 (a)). In addition, lipo T20 exhibited significantly better stimulation
than other lipid-modified oligonucleotides, showing an improved EC50 and potency of
IMQ in human TLR7 reporter cells (Figure 5-8 (b)). As for human TLR8 signaling, lipo
T20 did not affect the stimulatory potency of TLR8-506, a human TLR8 ligand. However,
lipo ODN 2087 suppressed TLR8-506 stimulation. In contrast, T20 remained efficacious
in potentiating TLR8 signaling in human TLR8 reporter cells (Figure 5-8 (c-d)), especially
at high TLR8-506 concentrations. Overall, these results suggested the feasibility of
applying lipo T20 and analogs to human models.

Figure 5-8. (a) HEK hTLR7 reporter cells were stimulated with 2 μM IMQ alone or
in combination with 1 μM T20 or lipo T20, 1 μM IRS 954 or lipo IRS 954, 1 μM ODN 2087
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or lipo ODN 2087 respectively for 24 h, (b) HEK hTLR7 reporter cells were stimulated
with IMQ at indicated concentrations alone or in combination with 1 μM T20 or lipo T20
for 24 h, (c) HEK hTLR8 reporter cells were stimulated with 1 μg/ml TLR8-506 alone or
in combination with 1 μM T20 or lipo T20, 1 μM ODN 2087 or lipo ODN 2087 respectively
for 24 h, (d) HEK hTLR8 reporter cells were stimulated with TLR8-506 at indicated
concentrations alone or in combination with 1 μM T20 or lipo T20 for 24 h. Data show the
mean values ± SEM. *, p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001; ns, not
significant by one-way ANOVA with Bonferroni post-test.
5.3.5 Ex vivo evaluation of adjuvant booster

Figure 5-9. (a-d) Murine splenocytes were stimulated with 2 μM IMQ alone or in
combination with 1 μM T20 or lipo T20 for 24 h, and the inflammatory cytokines and type
I IFN secreted by splenocytes including IL-6 (a), IL-12p40 (b), TNF-α (c), IFN-α (d) were
measured by ELISA, (e) Representative flow cytometry plots of pDC enriched from
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human PBMC, (f) human pDC cells

were stimulated with 2 μM IMQ alone or in

combination with 1 μM T20 or lipo T20 for 24 h, and IFN-α secreted by pDC cells was
determined by ELISA, (g) Human PBMC cells were stimulated with 60 nM TLR8-506
alone or in combination with 1 μM T20 or lipo T20 for 24 h, and TNF-α secreted by PBMC
cells was determined by ELISA. Data show the mean values ± SEM. *, p < 0.05; **, p <
0.01; ***, p < 0.001; ****, p < 0.0001; ns, not significant by one-way ANOVA with
Bonferroni post-test.
To evaluate the adjuvant enhancing activities of lipo T20 in primary immune cells,
we isolated splenocytes from mice spleens and stimulated them with IMQ as previously
described in TLR7/8 reporter cells. Consistent with our previous findings in the reporter
cells, lipo T20 markedly potentiated the potency of IMQ by upregulating the production of
NF-κB-signaled pro-inflammatory cytokines including IL-6, IL-12p40, and TNF-α, while
IMQ mixed with T20 led to a significantly lower level of pro-inflammatory cytokines
compared with IMQ alone (Figure 5-9 (a-c)). Interestingly, we observed that both T20
and lipo T20 decreased the production of IFN-α induced by IMQ (Figure 5-9 (d)). As
secretion of IFN-α from pDC was mainly regulated through IRF7 signaling but
independent of NF-κB activation,99 the results suggested that lipo T20 primarily intensified
TLR7-signaled NF-κB activation but was still able to inhibit TLR7-meidated production of
IFN-α.
Using human pDC enriched from human PBMC with 55.7% purity (Figure 5-9 (e)),
we further confirmed that lipo T20 partially conserved T20’s capability of downregulating
TLR7-mediated activation, evidenced by almost no secretion of IFN-α from pDC treated
with IMQ and lipo T20 (Figure 5-9 (f)). Interestingly, we observed that lipo T20 was able
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to significantly increase the production of TNF-α when mixed with TLR8-506 to treat
human PBMC (Figure 5-9 (g)). However, we demonstrated that lipo T20 had no impact
on TLR8-mediated NF-κB activation which regulated the production of pro-inflammatory
cytokines including TNF-α. Although underlying mechanisms remained unknown, one
possible interpretation was that lipo T20 mixed with TLR8 ligand might simultaneously
activate various immune cells in PBMC, which led to TLR8-mediated NF-κB activation.
These data emphasized specific innate immune activation pathways that lipo T20
possibly acted on, and it also suggested that lipo T20 could be a dual-booster for TLR7
and TLR8 adjuvants, which might be applied in clinical practice.
5.3.6 Adjuvant booster enhances immune responses of molecular vaccines in
vivo

Figure 5-10. (a) Representative flow cytometry plots of H-2Kb/SIINFEKL tetramer
staining of CD8+ cells, (b) Quantification of H-2Kb/SIINFEKL tetramer staining of CD8+
cells, (c) Quantification of IFN-γ-secreting CD8+ T cell determined by intracellular
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cytokine staining, (d) Quantification of TNF-α-secreting CD8+ T cell determined by
intracellular cytokine staining, (e) On day 20, serum samples were collected and
assayed by ELISA for anti-OVA IgG production. Data show the mean values ± SEM. *,
p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001; ns, not significant by one-way
ANOVA with Bonferroni post-test.
We revealed that lipo T20 improved the stimulatory potency and efficacy of IMQ in
the presence of albumin. In fact, interstitial space in the body harbors considerable serum
albumin which circulates through lymphatic system back to bloodstreams.100 Therefore,
lipo T20 theoretically was able to hijack interstitial albumin and then leverage it for
intensifying the potency of TLR7/8 ligands in the LNs. Previous studies reported that
unmodified IMQ showed little accumulation in the LNs while lipo T20 was able to target
APCs in the LN via ‘albumin-hitchhiking’.2,101 Besides, our data showed that lipo T20
amplified IMQ-induced immune activation in TLR reporter cells. Thus, we hypothesized
that subcutaneous administration of lipo T20 would improve the adjuvant effect of IMQ
and immune activation. To test this hypothesis, we immunized mice with model antigen
ovalbumin adjuvanted with a low dose of IMQ in the presence or absence of 6.2 nmol lipo
T20. Unformulated IMQ + OVA did not elicit detectable antigen-specific CD8+ T cells in
blood, presumably due to the insufficient LN draining of IMQ. However, the addition of
lipo T20 resulted in an approximate five-fold increase in OVA-specific CD8+ T cells and
up to a four-fold expansion of IFN-γ-secreting and TNF-α-secreting CD8+ T cells, as well
as significantly improved OVA-specific IgG titers in mice (Figure 5-10).
These results demonstrated that lipo T20 could function as a potent TLR7/8
adjuvant booster to potentiate immune responses induced by the molecular vaccine in
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vivo. Thus, lacing vaccine formulation with the adjuvant booster represents a novel and
simple approach to amplify the immunogenicity of subunit vaccines. The concept of
adjuvant enhancers can be immediately applied to current molecular vaccines adjuvanted
by TLR7/8 ligands, providing a plug and play approach to catalyze the development of
next-generation cancer vaccines.
5.4 Conclusions
In summary, we found that lipid-modified oligonucleotide-based TLR7/8 inhibitors
were able to improve the potency and efficacy of TLR7/8 ligands in the presence of
albumin. We found that these lipo ODNs could tolerate a wide range of sequences, but
the structurally-optimized lipo poly (dT) (20-25 nucleotides) showed maximal enhancing
effects. In addition, we found that lipo T20 was also applicable to human cells and was
able to enhance human TLR7- and TLR8-mediated NF-κB stimulation. However, lipo T20
still conserved the immunosuppressive capability of reducing TLR7-mediated production
of IFN-α in both murine and human cells. More significantly, lipo T20 was proved to be a
powerful adjuvant enhancer in enhancing the immune responses to molecular vaccines,
as lacing subunit vaccine formulation with lipo T20 led to markedly improved cellular and
humoral responses in mice. This finding might be broadly applicable in many current
vaccines, where both efficacy and safety are needed.
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CHAPTER 6 SUMMARY AND OUTLOOK
The major focus of this dissertation is to expand the research scope of the
“albumin-hitchhiking” approach. We mainly studied the therapeutic efficacy and
immunological properties of a variety of lipid-modified ODNs that were utilized for immune
modulation through LN-targeting delivery. For stimulatory ODNs, we showed that lipid
modification compromised the immunological activities of CpG ODNs in vitro, while lipidmodified class B and C CpG ODNs were able to markedly enhance the immunogenicity
of subunit vaccines in mice. In addition, lipid modification dramatically increased the
accumulation of CpG ODNs in LNs and reduced CpG-associated systemic toxicity.
Collectively, this study highlights the significance of targeted delivery to local LNs and
suggests that the “albumin-hitchhiking” approach holds great promise in optimizing
therapeutic efficacy of cancer vaccines while minimizing adjuvants-related side effects.
On the other hand, lipid modification on suppressive ODN A151 resulted in the greater
inhibitory capability of suppressing TLR9-mediated immune activation and enhanced
cellular uptake. Besides, compared to unmodified ODN A151, lipid-conjugated ODN A151
showed increased LN accumulation and demonstrated markedly improved therapeutic
efficacy in suppressing immune responses induced by CpG-adjuvanted vaccines in vivo.
These findings indicate that targeting suppressive ODN to LNs via hitchhiking
endogenous albumin may be a promising approach to potentiate immunoinhibitory
properties of suppressive ODN. In future works, we look forward to targeting other
immune modulators to local LNs to manipulate immune responses for the treatment of
autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus.
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Based on the intrinsic membrane-insertion properties of amphiphilic molecules, we
developed cell-based delivery strategies for systemic administration of therapeutics.
Specifically, we studied the structure-dependent stability of lipid-based amphiphiles
anchored on RBCs. The data revealed that longer diacyl lipid chain and short PEG spacer
contributed to more stable retention kinetics of amphiphiles loaded on RBCs in vivo. More
importantly, we observed that cationic lipid-modified amphiphiles exhibited exponentially
prolonged circulation half-life on RBCs in vivo relative to anionic lipid-conjugated analogs.
This research demonstrated a simple yet efficient cellular-hitchhiking delivery strategy
and emphasized the importance of rational structure design in in vivo stability of
amphiphiles anchored on RBCs. Many research directions may be developed based on
these findings. For example, loading amphiphilic chemotherapeutic drugs on RBCs
through spontaneous insertion may significantly extend their circulation half-life in vivo
and circumvent rapid immune clearance, and thus it may lead to sustained tumor killing
and achieve remarkable therapeutic efficacy in cancer treatment. In parallel, by
leveraging immunological properties of RBCs, amphiphilic peptides that hitchhike RBCs
may evade immune surveillance and stimulation and thus induce systemic tolerance
towards self-antigens that trigger autoimmunity. Hence, the “RBC-hitchhiking” approach
may hold great promise in treating autoimmune disorders as well.
More importantly, we discovered a novel class of lipid-modified oligonucleotidebased adjuvant booster which could enhance the adjuvant potency of TLR7/8 ligands in
vitro and in vivo. We explored the underlying mechanism by which lipid modification
converted oligonucleotide-based TLR7 inhibitors into TLR7 adjuvant boosters. The data
revealed that albumin was playing a pivotal role in the functional reversal of lipid-modified
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TLR7 inhibitors. Furthermore, we showed that lipid-modified oligonucleotide-based
adjuvant booster was applicable to human cells and could enhance human TLR7- and
TLR8-mediated NF-κB stimulation. More strikingly, the results demonstrated that
subcutaneous administration of imiquimod-adjuvanted vaccine laced with the adjuvant
booster in mice markedly enhanced antigen-specific cellular and humoral responses,
compared to the same vaccine without the adjuvant booster. Current strategies that are
employed to enhance the immunogenicity and safety of vaccines mainly focus on refining
the delivery efficiency of therapeutics to manipulate immune responses while minimizing
systemic toxicity. The concept of adjuvant booster-laced “molecular vaccine cocktail”
features a simple, novel and effective approach to considerably boosting the potency of
vaccine adjuvant and subsequently improving the immunogenicity of therapeutic vaccines.
The future work may further explore the molecular and structural mechanism by which
adjuvant boosters act on TLR7/8-mediated immune activation. By studying and
understanding the constitutive mechanisms, we may be able to design and engineer
biomolecules in a more rational way to modulate immune activation and achieve optimal
efficacy of cancer vaccines for clinical application. Another future research topic that may
be derived from this study may focus on the application of adjuvant booster in some
representative tumor models combined with current cancer vaccines, with the goal to
reverse tumor-associated immunosuppression and lead to tumor regression. Accordingly,
we will set out to investigate the efficacy of adjuvant booster in maximizing the
immunogenicity of cancer vaccines while minimizing systemic inflammatory reactions
induced by vaccine adjuvants in tumor models.
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Immunotherapy is emerging as one of the most promising therapeutic strategies
for cancer treatment in clinical practice. Immunotherapy leverages the host’s immune
system to attack and kill tumor cells. Rationally-designed cancer vaccines are emerging
as one of the powerful immunotherapies primarily because of the promise of inducing
potent anti-tumor immunity and eradicating tumors. To improve the immunogenicity of
cancer vaccines, vaccine antigens are administered with vaccine adjuvants which can
robustly activate the innate immune system and subsequently lead to adaptive immune
responses. However, the major challenge of achieving significant therapeutic efficacy is
the lack of efficient targeted delivery of vaccine components. By taking advantage of
endogenous albumin, lipid-modified oligonucleotides-based adjuvants can be efficiently
transported to draining lymph nodes (dLNs), where a variety of immune cells reside, and
subsequently activate the adaptive immune system. This “albumin-hitchhiking” strategy
represents a novel and efficient way for LN-targeted delivery of biologics, improving the
therapeutic efficacy of cancer vaccines.
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The aims of this dissertation are to further expand the scope of the “albuminhitchhiking” approach in immune modulation. We first evaluated the efficacy of three
representative classes of lipid-modified CpG ODNs as vaccine adjuvants. Lipo CpG
ODNs considerably drained to LNs more than unmodified CpG ODNs, while they
appeared to be functionally compromised in in vitro immune activation. However,
administration of lipo CpG class B and C ODNs, not lipo CpG class A ODN, with a protein
antigen in mice led to improved antigen-specific CD8+ T cell responses and humoral
responses relative to their parent compounds. We then evaluated the therapeutic efficacy
of immunosuppressive ODN A151 and its lipid-modified form in inhibiting TLR9-mediated
immune activation. The data showed that lipo ODN A151 was preferentially internalized
by cells and accumulated in LNs in a larger magnitude compared to unmodified ODN
A151. More importantly, prophylactic administration of lipo ODN A151, but not unmodified
ODN A151, resulted in profound inhibition of immune responses challenged and induced
by CpG-adjuvanted vaccines in mice. Next, we investigated the structure-dependent
stability of lipid-modified amphiphilic polymers on red blood cells (RBCs). We revealed
that longer lipid chain was correlated with more stable insertion on RBCs surface ex vivo,
while shorter polyethylene glycerol (PEG) spacer favored amphiphiles with more lasting
retention on RBCs in vivo. Furthermore, cationic amphiphiles constructed with cationic
lipids demonstrated significantly improved retention kinetics on RBCs in vivo, evidenced
by a 40-fold increase in circulation half-life relative to anionic counterparts. Finally, we
discovered a novel adjuvant enhancer which potentiated the adjuvant activities of TLR7/8
ligands in vitro and in vivo. The results showed that certain amphiphilic oligonucleotides
could improve TLR7 ligand-induced NF-κB activation in the presence of albumin protein.
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In vivo, administration of imiquimod-adjuvanted vaccine mixed with the structurallyoptimized amphiphilic oligonucleotide-based adjuvant booster induced a five-fold
increase in the frequency of antigen-specific CD 8+ T cells and the production of antigenspecific IgG in mice, compared to the same vaccine without adjuvant booster. Accordingly,
lipid-functionalized oligonucleotide-based adjuvant booster could dramatically improve
the immunogenicity of subunit vaccines. Collectively, lipid-functionalized oligonucleotides
not only accumulate in LNs by hitchhiking endogenous albumin but also versatilely
modulate the immune responses. Amphiphilic oligonucleotides may be broadly employed
for the treatment of diseases involving the immune system, where the immune modulation
is needed.
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